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Abstract 
Hormones are critical regulatory factors produced by the body to regulate diverse 
physiological activities such as energy homeostasis, growth and differentiation of a 
diverse array of tissues, sexual maturation and development of secondary sexual 
characters. Cytokines are hormones, which predominantly regulate growth, 
proliferation differentiation, immunomodulation and tumor progression. They act 
in endocrine, paracrine or autocrine manner, and elicit their action by binding to a 
cell surface receptor and activating diverse intracellular signaling cascades.  
Prolactin (PRL) is a peptide hormone, encoded by the PRL gene located on 
chromosome 6 in humans. This gene is under the control of two independent 
promoters, the pituitary promoter which regulates its expression from the 
lactotroph cells of the anterior pituitary and an extrapituitary promoter which 
regulates its expression from extra-pituitary tissues such as endometrium, placenta, 
breast and a variety of tumors. PRL in humans binds specifically to PRL receptor 
(PRLR), to cause intracellular changes modulated mainly via the JAK-STAT or 
JAK-STAT-ERK pathways. Historically, PRL has been studied as an endocrine 
hormone that regulates lactation during pregnancy. However, the identification of 
extra-pituitary PRL and the complex clinical consequences of hyperprolactemia 
have prompted investigators to reevaluate its role in regulating other physiological 
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aspects. Studies from several groups over the last few decades have shown that 
PRL can regulate a spectrum of functions ranging from behavior to immune 
responses to tumorigenesis.  
Cancer is a growth disorder which was mentioned as early as 460-370 BC, by 
Hippocrates who coined the term “cancer” based on its appearance post-surgery. 
Throughout history, cancer has been the cause of severe physical and emotional 
suffering and death in humans and animals alike. Cancer has an exceptional 
capability to take over body’s normal physiology, modulate it and uses it for its 
own growth and to overcome anti-cancer treatment. Over the last several decades, 
research efforts from several laboratories have helped gain a better understanding 
of the molecular mechanisms that regulate cancer initiation, development and 
progression. These studies have also provided new insights for identifying and 
developing new pharmaceutical compounds to target tumor cells. 
Colorectal cancer (CRC) is the third leading cause of cancer related death in 
United States. Worldwide, up to 5% of all reported cancer cases are due to CRC, 
with 60% of them being diagnosed in industrially developed or developing 
countries.  CRC is caused by genetic and environmental factors. Environmental 
factors ranging from changing dietary habits to environmental toxins are associated 
with the development of CRC. Germline mutations in APC, TP53 and DNA 
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mismatch repair genes gives rise to familial inheritable form of CRC and 
contribute to nearly 35% of the registered CRC cases. 
This dissertation outlines the expression pattern of PRLR and the cellular 
mechanism(s) which are regulated or activated by PRL- PRLR signaling and the 
contribution of this signaling towards pathogenesis of CRC. 
We have determined that CRC cells treated with recombinant human PRL show a 
time- and dose-dependent phosphorylation of JAK2, STAT3 and ERK1/2 proteins. 
Previous studies have demonstrated that breast cancer cells treated with PRL show 
a rapid induction of STAT5 phosphorylation. However, in our studies, we found 
that colon cancer cells treated with PRL show an induction of STAT3 
phosphorylation. This may be in part due to low basal level of STAT5 in colon 
cancer cells. In addition, PRL treatment does not lead to increase in proliferation, 
falling in line with earlier observations, that STAT3 is not a proliferation 
promoting factor. Pre-incubating CRC cells with AG490 and PD98059 which are 
established JAK2 and ERK1/2 inhibitors prior to PRL treatment led to a complete 
abrogation of respective phosphorylation, suggesting that the observed activation 
of JAK2 and ERK1/2 is indeed induced by PRL in CRC cells. 
PRL treatment induces spheroid formation, a hall mark of cancer stem cells and 
does so, by activating Notch signaling. The Notch signaling pathway is critical in 
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maintaining cancer stem cell populations both in vitro and in vivo. PRL activates 
Notch signaling by inducing the expression of Jagged 1(JAG1), a Notch receptor 
ligand. Binding of JAG1 to Notch receptor induces conformation changes in the 
receptor, leading to its cleavage and translocation of the cleaved intracellular 
domain (NICD) into the nucleus where it activates expression of Notch responsive 
genes. PRL treatment induces a time dependent increase in Notch cleavage. In 
addition, an increase in expression of Hes1 and Hey1, established Notch target 
genes, clearly implicate PRL treatment in activation of Notch signaling in colon 
cancer cells. In addition, the treatment induced expression of established colon 
cancer stem cell marker proteins such as LGR5, DCLK1 and CD44 suggests that 
PRL contributes towards modulating colon cancer stem cell population. Pretreating 
CRC cells with AG490 and PD98059, leads to loss of Notch activation and 
decreased expression of cancer stem cell marker proteins, again implicating the 
role of PRL in modulating the Notch signaling, thereby playing a critical role in 
regulating colon cancer stem cell population. 
One of the critical aspects associated with human PRL signaling is its receptor 
specificity. Human PRL can bind only to PRLR, which is a specific PRL receptor. 
Our findings indicate that PRL can modulate critical aspects associated with 
colorectal cancer. We were interested in examining the expression pattern of PRLR 
in colorectal cancer patients with an aim to develop novel diagnostic tools or 
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therapeutically target PRL signaling. Our findings clearly indicate that PRLR is 
expressed in normal tissues throughout the GI tract, with predominant expression 
in the large intestine. Additionally, PRLR expression is significantly increased in 
colorectal cancer biopsy samples compared to adjacent normal samples. This 
suggests that PRL signaling can play a critical role in colorectal cancer 
tumorigenesis. A couple of factors may contribute to the increase in expression of 
a gene: first being an increase in copy number of the gene and second being an 
enhanced transcription of the gene. In order to examine the existence of 
chromosomal variation, we analyzed TCGA data sets pertaining to expression and 
copy number data. Data analysis suggested the possibility of an increase in copy 
number of not only PRLR but also of a couple other genes located in the vicinity in 
some patients. Among the other patients, some had an increase in expression 
without any change in copy number. To identify the reason for increased 
expression of PRLR in these patients, we evaluated the possibility of tumor 
specific transcription factor binding and subsequent increase in PRLR 
transcription. We analyzed a 2 Kb upstream region of the PRLR promoter and 
identified binding sites for SREBP-1, a transcription enhancer that regulates 
expression of enzymes necessary for lipid metabolism and energy homeostasis. 
SREBP-1 is highly expressed in colorectal tumors. Studies using ChIP and RT-
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PCR analysis indicate that SREBP-1 is actively recruited to the PRLR enhancer 
region and can potentially be involved in regulating its expression.  
Collectively, this dissertation provides novel insights into the role of PRL in 
colorectal tumorigenesis. It also implicates the critical role of PRLR signaling in 
colorectal cancer and suggests that PRLR can be exploited as a diagnostic marker. 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
Acknowledgements 
At the onset, I would like to thank my mentor Dr. Shrikant Anant. I have learnt a 
lot by being part of his academic group. He allowed me to start a project that is 
quiet distant from the labs general work arena and trusted me with the task of 
initiating and always had time to discuss the drawback that I encountered and gave 
suggestions or directed me to a person who can be most suitable. He always 
ensured that the work is never hindered and always strived to provide the necessary 
financial stability that is needed to the science in the lab to progress. Being a very 
collaborative personality, he encouraged me to reach out to other labs to learn the 
necessary techniques or to get some reagents that are necessary to address the 
hypothesis, for which I am very grateful.  He encouraged me to test my ideas and 
hypothesis even if he thought it may not work, just so that, I would benefit of 
learning from my own experience. The weekly, one-on-one meeting and the lab 
meetings helped me develop a comprehensive awareness of how to work and how 
to address criticism in science. 
Next I would like to thank my committee members Dr. Paul Terranova, Dr. Roy 
Jensen, Dr. T. Raj Kumar and Dr. John Wood for all your valuable and timely 
suggestions and input on my work which helped me in putting a part of my work 
out for publication and  my overall progress towards my defense. I thank Dr. 
 
x 
 
Vincent Goffin from INSERM, France, for providing us with human recombinant 
prolactin. His collaboration and contributions in towards writing the paper were 
critical in taking the project forward. I would also like to thanks to Dr. Ossama 
Tawfik, with whom I have collaborated to analyze my histology staining. His 
suggestions and advice helped me consolidate a rather random data and make 
absolute scenes of it. I would also like to thank Dr. Andrew Godwin, Dr. Harsh 
Pathak and Dr. Andrew Godwin, for extending their collaboration in acquiring and 
analyzing the TCGA data sets  
I extend my thanks to the Anant lab members, Dharmalingam Subramaniam, 
Sivapriya Ponnurangam, Satish Ramalingam, Parthasarathy Rangarajan, Prabhu 
Ramamoorthy, Gaurav Kaushik, Deep Kwatra, David Standing and Sateesh 
Sainathan, for being my academic family and making my PhD a memorable 
experience. Although not all of my projects have worked well, I am indebted to 
everyone I worked with and everyone who shared their time and knowledge with 
me.  
I thank my fellow students Anand Venugopal, Jessica Johnson in the lab and in the 
department and in the Indian association for your good company and all the fun 
outings/activities that kept me going. I also thank the all the faculty members and 
 
xi 
 
staff in the department with whom I have interacted often as I have learnt 
something or the other from everyone I’ve met here. 
I also thank my previous mentors, Sisinthy Shivaji, Bhaskar Bhadra from CCMB, 
Hyderabad. Vishnupriya, Kavi Kishore and Dasavantha Reddy from Osmania 
University, Hyderabad. Penna Suprasanna and Viswas Manohar Kulkarni from 
BARC, Mumbai, India. Ms. Mary, Venkateshwara Rao, Veena and Narsimulu 
from Little Flower High School, Hyderabad, India. I also thank my father, 
Narasappa Naradukoma and my mother Bhagya Mamilla for their support and 
encouragement. My sister Mrs. Sangamithra Vijay Duddu, her support and help 
while applying to universities in US were critical in getting an admission into 
KUMC.  
One of the best things that happened in graduate school was that I got to meet my 
life partner Felcy Pavithra. She is a person with a passion for science and 
exploration. Her help and suggestions in putting my presentation together were 
critical in my success. Her overall awareness of the society and peoples thoughts 
has helped me learn the ways of talking with people and have kept me out of 
trouble. Her ideas and passion for science keep me motivated even in difficult 
times. Her presence makes life a beautiful experience. I also thank her for giving 
 
xii 
 
me a charming daughter Gowri Valora, who taught us that there is more to life than 
lab and work and keeps us cheerful and busy. 
Finally I thank God for all of my life’s blessings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
Dedication 
 
 
 
 
 
 
 
 
 
 
 
 
(Bhagvadgita Chapter 11: 43) 
 
I dedicate this dissertation to the preceptor of the universe. I thank him for giving 
me this opportunity to understand a small portion of his marvelous and mysterious 
creation.  
 
  
 
xiv 
 
Table of Contents 
Abstract           iii 
Acknowledgments          ix 
Dedication           xiii 
Table of Contents          xiv 
List of Abbreviation         xxi 
Chapter 1: Background and Introduction      1 
1.1 Cancer Statistics         2 
1.2 Intestine and its cellular architecture      3 
1.2.1 Anatomy of the intestine        3 
1.2.2 Cell types of the intestine        4 
1.3 Stem cells          5 
1.3.1 Intestinal stem cells (ISC)        5 
1.3.2 Cancer stem cells (CSC)        7 
1.4 Signaling pathways and markers of ISC and CSC    7 
 
xv 
 
1.4.1 Signaling pathways         10 
1.4.1.1 Notch signaling pathway       10 
1.4.1.2 Wnt signaling pathway        13 
1.4.1.3 Hedgehog signaling pathway       14 
1.4.1.4 Hippo signaling pathway       15 
1.4.2 ISC markers          16 
1.4.2.1 Doublecortin like kinase 1 (DCLK1)      16 
1.4.2.2 Leucin-rich-repeat-containing G-protein-coupled receptor 5 (LGR5) 17 
1.4.2.3 Other putative stem cells       18 
1.5 Colorectal cancer         19 
1.5.1 Genetic mutations in colorectal tumorigenesis    19 
15.1.1 Adenomatous polyposis coli (APC) gene mutation    22 
1.5.1.2 Tumor protein p53 (TP53) mutations      23 
1.5.1.3 Transforming Growth Factor Beta Receptor Type 2 (TGFBR2)  
            Mutations          24 
1.5.1.4 Mutations in RAS-BRAF and PI3K pathway genes   24 
 
xvi 
 
1.6 Growth factor pathway activation in colorectal cancer    25 
1.6.1 Prostaglandin E2         28 
1.6.2 Epidermal growth factor receptor      28 
1.6.3 Vascular endothelial growth factor      29 
1.7 Role of endocrine hormones in colorectal cancer    29 
1.8 Prolactin          30 
1.9 Prolactin and its role in normal development and pathologies  35 
1.9.1 Role of PRL in brain, stress, fertility and pregnancy    35 
1.9.2 Role of PRL in normal breast development and breast cancer  37 
1.9.3 Role of PRL in normal prostate development and prostate cancer 40 
1.9.4 Role of PRL in normal liver development and hepatological cancer 41 
1.9.5 Role of PRL in gynecological cancer      42 
1.9.6 Prolactin and its role in normal intestine     43 
1.9.7 Implication of prolactin in colorectal tumors     43 
1.9.8 Role of prolactin in stem cells       44 
 
xvii 
 
1.10 Prolactin receptor         50 
1.10.1 PRLR and its implication in pathologies and cancer   51 
1.10.2 PRLR and its implication in gastrointestinal cancer   53 
1.11 Prolactin signaling         53 
1.12 JAK-STAT signaling        55 
1.12.1 Role of JAK-STAT signaling in pathologies     59 
1.12.2 Significance of JAK-STAT signaling in colorectal cancer  60 
Chapter 2: Prolactin signaling enhances colon cancer stemness by  
                   modulating Notch signaling via JAK2-STAT3/ ERK pathway62 
2.1 Abstract           63 
2.2 Introduction          64 
2.3 Materials and methods        68 
2.3.1 Cells           68 
2.3.2 Spheroid assay         68 
2.3.3 RT-PCR analysis         69 
2.3.4 Western blot analysis and Enzyme linked Immunosorbent assay  72 
 
xviii 
 
2.3.5 Luciferase assay         75 
2.3.6 Statistical analysis         78 
2.4 Results           81 
2.4.1 PRLR but not PRL is upregulated in colon cancer cells   81 
2.4.2 PRL treatment induces STAT3 and ERK ½ phosphorylation  81 
2.4.3 PRL induces spheroid formation and is inhibited by JAK2 and 
         ERK inhibitors         85 
2.4.4 PRL induces expression of colon cancer stem cell marker genes  88 
2.4.5 PRL affects cancer stem and progenitor cells by inducing Notch  
Signaling          91 
2.4.6 Notch signaling is necessary to mediate PRL induced changes  95 
2.5 Discussion          98 
Chapter 3: Heterogeneity in expression of prolactin receptor in colorectal  
                  cancer          104 
3.1 Abstract           105 
3.2 Introduction          106 
3.3 Materials and methods        112 
3.3.1 Cell lines          112 
 
xix 
 
3.3.2 RT-PCR analysis         112 
3.3.3 Western blot analysis        113 
3.3.4 Histology          113 
3.3.5 ChIP assay          114 
3.3.6 Analysis of TCGA data sets       115 
3.3.7 Statistical analysis         115 
3.4 Results           117 
3.4.1 Expression of PRLR along the gastrointestinal tract    117 
3.4.2 Expression of PRLR in CRC and normal tissues    117 
3.4.3 Histological validation of PRLR expression in CRC and normal tissues 124 
3.4.4 Analysis of PRLR expression in metastatic sites    124 
3.4.5 TCGA based evaluation of changes in PRLR expression   125 
3.4.6 Intrinsic transcription factors which regulate PRLR expression  143 
3.5 Discussion          146 
Chapter 4 Discussion and future directions     152 
 
xx 
 
4.1 Discussion          153 
4.2 Intracellular pathways activated by PRL in CRC    154 
4.3 Expression pattern of PRLR in colorectal cancer    158 
4.4 Future Directions         161 
4.4.1 Analyzing PRLR locus amplification      161 
4.4.2 Identifying novel small molecular inhibitors to target  
         JAK-STAT signaling        161 
4.4.3 Evaluation SREBP-1 binding to the PRLR enhancer elements  162 
References           163 
 
 
 
 
 
                
 
 
 
 
xxi 
 
List of Abbreviations 
Abbreviation  Full name 
15- PGDH   15- prostaglandin dehydrogenase  
ADAM-TACE ADAM Metallopeptidase Domain 17/Tumor necrosis 
factor-α-converting enzyme 
AGXT2   Alanine-glyoxylate aminotransferase 2 
ALDH1   Aldehyde dehydrogenase 1 
APC     Adenomatose polyposis coli 
APH-1   Anterior pharynx defective-1 
bHLH   Basic helix-loop-helix 
BMI-1   Polycomb complex protein BMI-1 
CAE    Carcino embryonic antigen 
CaP    Prostate cancer 
CBC    Crypt based columnar cells 
CD44    Cluster of division-44 
cDNA   Complimentary DNA 
 
xxii 
 
CK-1    Casein kinase-1 
CNV    Copy number variation 
COX-2   Cyclooxygenase 2 
CRC    Colorectal cancer 
DCLK1   Double cortin like kinase 1 
E2    Esotrgen 
ECD    Notch Extracellular Domain 
EGF    Epidermal growth factor  
EGFR   Epidermal growth factor receptor 
ELISA   Enzyme linked Immunosorbent assay 
ER    Estrogen receptor 
FAP    Familial adenomatous polyposis 
FGF    Fibroblast growth factor 
Fz    Frizzled 
GH    Growth receptor 
 
xxiii 
 
GHR    Growth hormone receptor 
GSK-3β    Glycogen synthase kinase 3β 
IBD    Inflammatory bowel disease 
IRS2    Insulin receptor substrate 2 
ISC    Intestinal stem cells 
JAG1    Jagged 1 
JAK    Janus Kinase 
KGFR   Keratinocyte growth factor 
LBW    Liver to body weight 
LGR5   Leucin-rich repeat containing G-protein coupled receptor 
LRP    LDL receptor protein 
MAML   Mastermind like protein  
MAPK   Mitogen Activated Protein Kinase 
Min    Multiple intestinal neoplasia 
MMR    Mismatch repair 
 
xxiv 
 
mRNA   Messenger ribonucleic acid  
Msi-1    Musashi-1 
NECD   Notch extracellular domain 
NICD    Notch Intracellular Domain 
NICD    Notch intracellular domain 
NSAID   Non-steroidal anti-inflammatory drugs 
P4    Progesterone 
PDAC   Pancreatic ductal adenocarcinoma 
PEN-2   Presenilin enhancer-2 
PGE2    Prostaglandin E2 
PH    Partial hepatectomy 
PI3K    Phosphoinositol 3 kinase 
PKC    Protein kinase C 
PL    Placental lactogen 
PR    Progesterone receptor 
 
xxv 
 
PRL    Prolactin 
PRLR   Prolactin receptor 
PSEN-1   Presenilin 1 
PSENEN   Presenilin enhancer 
RBPJ    Recombining binding protein suppressor of hairless 
RT-PCR   Real time polymerase chain reaction 
SCID    Severe combined immuno-deficient mice 
SOCS3    Suppressor of cytokine signaling 3 
SRE-1   SREPB-1 response element 
SREBP   Steroid response element binding protein 
STAM   Signal transducing adapter molecules 
STAT    Signal transducers and activators of transcription 
TA    Transient amplifying cells 
TF    Transcription Factor/s 
TGCA   The cancer genome atlas 
 
xxvi 
 
TGFBR2   Transforming growth factor beta receptor 2 
TK    Thymidine kinase  
VEGF   Vascular endothelial growth factor 
 
1 
 
 
 
 
 
 
 
 
Chapter 1 
Background and introduction  
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1.1 Cancer Statistics 
The earliest mention of cancer can be traced to Hippocrates in 460- 370 BC. He 
coined the term “cancer” based on the appearance of the tissue mass post-surgery. 
Throughout the world, cancer is responsible for the severe physical and emotional 
suffering and death in both humans and animals. It has been proposed that most 
tumors are clonal in origin, which implicates arising from a single cell. During 
growth, this clonal cell acquires genetic variation and mutations which confer 
collective growth advantage to these cells leading to full-fledged cancer [1].  
Cancer constitutes a rising health issue in developed and developing countries. It is 
a major public health problem in the United States accounting for one in four 
deaths. Prostate cancer alone accounts for 28% of registered cancer related 
incidents in men. Breast, lung and bronchus, and colorectal cancers in women 
account for 51% of cancer cases. According to predictions based on clinical 
statistics, prostate cancer, lung and bronchial cancer, and colorectal cancers (CRC) 
will account for about 50% of all newly diagnosed cancers. It is estimated that 
between 500,000 to 600,000 Americans will be affected by cancer in 2014 [2].  
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1.2 Intestine and its cellular architecture 
1.2.1 Anatomy of the intestine 
The intestinal tract is a tube like organ lined with three concentrically arranged 
tissue layers. The outer smooth muscle layer is heavily innervated with nerve 
terminals which regulate the rhythmic peristaltic movements of the intestine. The 
inner luminal surface consists of a single-cell layer simple epithelium and an 
acellular mucosa (mucosal layer) responsible for nutrient absorption and stool 
compaction. The connective tissue called stroma fills the space between these two 
layers and contains blood and lymph vessels, nerve fibers, and immune cells [3]. 
The intestinal tract can be anatomically divided into two segments: the small 
intestine and the large intestine or colon. Small intestine forms the absorptive 
surface and has numerous finger-like protrusions called “villi” pointing into the 
lumen and invaginations called “crypts of Lieberkühn” which are embedded into 
the submucosa. These villi and crypts increase the absorptive surface of the 
intestine. The colon lacks villi but retains the deeply embedded crypts [4]. 
Prenatally and at birth, intestinal epithelial proliferation is limited to small pockets 
along the length of the intestine. A few weeks postnatally, clear and 
distinguishable villi and crypts begin to appear, spreading across the intestine. As 
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development progresses, the number of crypts continuously increases to 
accommodate the growth of the organ by dividing through a process called “crypt 
fission” [5].  
1.2.2 Cell types of the intestine 
The epithelial lining of the intestine has an average turnover time of 7-8 days and 
is routinely replaced by new cells. Four distinct cell types constitute the intestinal 
epithelium: the absorptive enterocytes, enteroendocrine cells, mucus secreting 
goblet cells and Paneth cells [3] (Fig 1.1). Enterocytes constitute the absorptive 
cells of the intestine and are more abundant in the small intestine. Each enterocyte 
possesses numerous villi like projections that increase the absorptive surface. 
These cells secrete digestive enzymes and help in absorption of digested nutrients 
from the lumen. Enterocytes of the colon are completely devoid of the villi 
structures. Goblet cells secrete mucus and play a role in stool compaction. Their 
population is high in the colon compared to the small intestine. Enteroendocrine 
cells secrete hormones like serotonin, substance P and secretin. Paneth cells, which 
reside at the bottom of each crypt, secrete antimicrobial agents such as defensins 
and lysozyme. These help in regulating and controlling intestinal microbial 
population. In addition, crypts of both the small intestine and colon harbor a 
distinct stem cell population. These stem cells are located at the base of the crypt 
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and can regenerate the cell types lining the intestine [6]. The relative abundance of 
each cell type differs depending on the context of the segment; small intestine has 
a relative abundance of absorptive enterocytes, while the population of mucous 
secreting goblet cells increases in the colon [4].  
1.3 Stem Cells 
Stem cells are pluripotent cells that can differentiate into cells of diverse tissue 
types. They were first isolated and identified by Martin Evans in mouse blastocysts 
[7]. Human stem cells were identified and isolated by James Thompson from 
human blastocysts [8]. Later, stem cells were identified in several tissue types and 
are thought to be responsible for routine tissue regeneration. Hematopoietic stem 
cells were the first to be identified [9]. Stem cells of the intestine are located at the 
base of the crypt and have the potential to regenerate all of the cell types of the 
crypt [10].  
1.3.1 Intestinal stem cells (ISC) 
Stem cells of the crypt as described earlier are present at the base of the crypt and 
are critical in regenerating various cells of the intestinal epithelium [6], however, 
there are a few of these cells in the intestine. For more than a century, crypt stem 
cells were thought to be localized in a “proliferative zone” below the Paneth cells. 
Label retaining experiments by Potten et al., clearly demonstrated that cells located 
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at the 4
th
 position (+4 position) from the base of the crypt constitutes the stem cell 
population [11] (Fig 1.1). These cells divide asymmetrically to produce a +4 cell 
and a transient amplifying cell (TA) [11]. 
3
H-thymidine and BrdU incorporation 
studies including immunochemical labeling using Ki67 have shown that TA cells 
constitute the rapidly dividing cells of the intestine, with a cycling time of 12- 14 
hours and are capable of differentiating into all four cell types of the of the crypt-
villi axis. Both +4 cells and TA cells are pluripotent and can generate all of the 
intestinal cell types of the crypt-villus axis [10]. Radiation studies identified that 
+4 cells are generally resistant to low dose radiation but not high doses, a feature 
that protects the stem cells from genetic damage. In this model, TA cells help 
reestablish the stem cell population by falling into the +4 position to dedifferentiate 
into stem cells [12]. A second school of thought proposed by Leblong, Cheng and 
Bjerknes, believes that Crypt Base Columnar (CBC) cells, located at the base of 
the crypt, interspersed between Paneth cells, are small and undifferentiated, and 
constitute the stem cell population [13, 14] (Fig 1.1).  
Irrespective of their origin (+4 cells or CBC), ISC’s are critical in maintaining 
normal GI architecture and dysregulations in the ISC population can lead to 
neoplastic growth. Various factors, intrinsic or extrinsic, can contribute to this 
dysregulation and eventually lead to development of GI cancers. 
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1.3.2 Cancer stem cells (CSC)  
CSCs were initially identified in human leukemia as a distinct group of cells 
capable of proliferation and self-renewal [15]. Singh and colleagues later identified 
in disintegrated brain tumors that CSC also express normal neural stem cell surface 
markers and were able to form neurospheres when cultured in adhesion free 
conditions. The number of these cells varied with tumor grade with high numbers 
in more aggressive tumors compared to benign forms [16]. Later research 
identified cancer stem cell population in diverse cancer types including breast [17], 
melanoma [18], ovarian [19], prostate [20], and colorectal cancer [21]. It is now 
well established that cancer stem cells are resistant to therapeutic interventions, 
responsible for tumor recurrence after a successful therapeutic intervention and 
ensure continued growth of the tumor [22]. Current therapeutic development 
research is directed towards targeting the CSC population. In spite of the 
awareness of the existence of CSC, an equal number of investigators argue against 
the existence of a distinct CSC population.  
1.4 Signaling pathways and markers of ISC and CSC  
ISC are thought to be located in a niche that regulates the balance between stem 
cell renewal and tissue regeneration. A number of signaling pathways are active 
and regulate the establishment of this niche and proliferation of ISC. 
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Figure 1.1: Structure of a colonic crypt:  Colon consists of deeply embedded 
crypts, which are lined by columnar epithelial cells called enterocytes. Enterocytes 
can be categorized as crypt based columnar cells (CBC) and +4 DCLK1 and LGR5 
positive cells, which make up the stem cells and transient stem cell population, 
mucin secreting Paneth cells, hormone secreting enteroendocrine cells and goblet 
cells. Moving along the crypt axis, the Wnt signaling pathway, critical for 
maintaining stem cell population, is active at the base and decreases in activity as 
we move up the axis. Whereas, Notch signaling, active in transient amplifying 
cells, increases in activity as we move up the crypt axis. 
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Genetic studies have provided evidence that the Wnt/ β-catenin signaling is 
important for ISC maintenance and self-renewal. Notch signaling pathways 
regulate ISC fate and differentiation, while BMP, secreted by the mesenchymal 
cells surrounding the crypt, down regulates both Wnt/ β-catenin and Notch 
signaling and induces differentiation [23] (Fig 1.1).  
1.4.1 Signaling pathways 
1.4.1.1 Notch signaling pathway 
Notch signaling is a pathway that is active in intestinal stem cells and contributes 
significantly to stem cell proliferation and differentiation (Fig 1.2). It is involved in 
regulating stem cell hierarchy and determining cell fate [24] and is active in the 
intestinal crypts [25]. The Notch family of receptors consists of four 
transmembrane proteins designated as Notch 1- 4. Each Notch receptor consists of 
an extracellular domain (NECD) and intracellular domains (NICD). These domains 
are translated as a single protein; however, this peptide undergoes S1 cleavage and 
is later bound by disulfide linkages and held across the membrane. Notch receptor 
ligands (Jagged 1, 2 or Delta 1, 3, 4) are single pass transmembrane proteins that 
are localized on adjacent cell membranes. Binding of the ligand with the receptor 
leads to a conformational change in the Notch receptor leading to S2 cleavage. 
This cleaves off the Notch extracellular domain (NECD) and activates the γ- 
 
11 
 
Figure 1.2: Notch Signaling 
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Figure 1.2: Notch Signaling: Notch signaling is necessary for maintain the crypt 
transient stem cell pool. Notch receptor and ligands are both transmembrane 
proteins. Interaction of the ligand to the notch extracellular domain (ECD), leads to 
a conformational change in the receptor, opening up cleavage sites initially to be 
acted upon by protease tumor necrosis factor α-converting enzyme (ADAM-
TACE) (S2 cleavage) and later by the  proteins of the γ-secretase complex (S3 
cleavage), leading to release of the notch intracellular domain (NICD). NICD 
translocates into the nucleus to form a transcription initiating complex with Master 
Mind (MAML) and CBF1/ suppressor of hairless-1 (CSL) proteins and activates 
transcription of Notch responsive genes. 
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secretase complex consisting of  Presenilin, Nicastrin, Anterior Pharynx Defective 
1 (APH 1) and Presenilin enhancer 2 (PEN-2) proteins, which leads to the last S3 
cleavage, resulting in the release of the Notch intracellular domain (NICD) [26, 
27]. Cleaved NICD would translocate into the nucleus and bind to transcription 
enhancer proteins Mastermind and RBPJ, leading to the activation of Notch target 
genes. Hes-1 and Hey1 have long serves as a powerful target of Notch activation 
[28], and can be used to assess the degree of Notch signal activation. Constitutive 
Notch activation is necessary for intestinal stem cell maintenance [29] and 
deregulation of this pathway have been observed in CRC and other forms of cancer 
[30, 31]. 
1.4.1.2 Wnt signaling pathway 
Canonical Wnt signaling is active at the crypt base and is critical in maintaining 
the colonic stem cell population. Wnt genes were initially identified in Drosophila 
melanogaster as factors that regulate the segmental behavior of larval development 
[32], and were later identified as the gene that is activated in virally induced breast 
tumors [33]. It is thought that perycryptic myofibroblasts produce the Wnt ligand 
that can bind to its cognate receptors located on the adjacent crypt base cells.  Wnt 
receptor consist of a seven transmembrane domain containing Frizzled (Fz) 
proteins, that would bind to the Wnt ligand in the presence of LDL receptor protein 
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(LRP), also a single pass transmembrane protein to activate intracellular signaling. 
β-catenin is one of the critical intracellular proteins, which mediates canonical Wnt 
signaling. Binding of β-catenin to the TCF-LEF enhancer complex localized in the 
promoter regions of the Wnt responsive genes, regulates the expression of these 
genes. β-catenin has a very low turnover and in the absence of Wnt ligands, it 
forms a complex with Adenomatous polyposis coli (APC), Glycogen synthase 
kinase 3 β (GSK 3β), Axin and Casein Kinase-1 (CK-1). Phosphorylation of β-
catenin mediated by CK1 and GSK 3β, directs it to ubiquitin-mediated 
degradation.  Binding of Wnt ligand to the heterodimeric Fz and LRP receptor 
leads to CK1 mediated phosphorylation LRP receptor. Phosphorylated LRP acts as 
binding site for the Auxin causing a conformational change in the protein leading 
to the release of APC and β-catenin, which can eventually translocate into the 
nucleus and activate gene expression [34, 35].  Mutations in components of this 
pathway have been implicated in inheritable CRC, as described below.  
1.4.1.3 Hedgehog signaling 
The hedgehog (hh) gene was identified from genetic screens aimed at evaluating 
genes involved in body segmentation in Drosophila melanogaster [32]. 
Orthologous signaling pathway was later identified in higher vertebrates including 
humans. In humans and rodents, hedgehog signaling is involved in embryogenesis, 
tissue homeostasis, tissue repair and tumorigenesis by modulating stem cells [36]. 
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Three Hh family ligands have been identified in humans: Sonic hedgehog (SHH), 
Indian hedgehog (IHH) and Desert hedgehog (DHH). These ligands undergo auto 
processing and lipid modifications to generate mature proteins [37]. In the absence 
of the ligands, Patched family receptors (PTCH1 and 2) will interact and inhibit 
Smoothened (SMO) signal transducer protein. Sequestration of SMO leads to 
formation of GLI degradation complex. This complex is composed of casein 
kinase Iα (CKIα), glycogen synthase kinase- 3β (GSK-3β) and protein kinase A 
(PKA) and would bind to GLI proteins and phosphorylate them leading to their 
ubiquitin mediated degradation [38]. Binding of hedgehog ligand to the Patched 
receptor leads to release of SMO, which is later activated by STK36 (Serin/ 
threonine kinase), preventing formation of the GLI degradation complex, leading 
to stabilization and nuclear translocation of GLI proteins. Hedgehog signaling 
activates and leads to GLI-dependent transcriptional activation of target genes like 
Cyclin D2, FoxL1 and Jagged 2 [39].  
1.4.1.4 Hippo signaling pathway 
The Hippo signaling pathway was discovered in Drosophila melanogaster and 
regulates organ size across species [40]. Deregulation in this pathway is associated 
with disease and cancer in various tissues. Hippo pathway modulates tissue/ tumor 
size by directly regulating stem cell proliferation and maintenance [41]. Canonical 
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Hippo signaling pathway is mediated mainly by MST1/2 and LATS1/2 serine 
kinases that inhibit the YAP and TAZ transcriptional cofactors by phosphorylating 
them on Ser127 and Ser89, respectively. YAP and TAZ activate TEAD and other 
transcription factors to regulate gene expression. YAP and TAZ can also regulate a 
plethora of other activities including tumorigenesis. YAP expression is typically 
restricted to the crypt compartment.  Expression of constitutively active YAP 
(YAP-S127A) protein in the intestine leads to expansion of undifferentiated cells 
in the crypt. A similar phenotype is observed when YAP protein is activated in the 
skin. Along similar lines, conditional deletion of MST1/2 lead to an intestinal 
phenotype similar to that of the YAP overexpressing model, with an increase in 
stem cell population.  Canonical Hippo components SAV1 and MST1/2 actively 
restrict nuclear translocation of YAP in the ISCs, thus regulate their proliferation 
under normal conditions. Under pathological conditions such as CRC, active 
Hippo signaling together with Wnt and Notch signaling contribute to tumor 
progression by modulating ISC population [40]. 
1.4.2 ISC markers 
1.4.2.1 Doublecortin like kinase 1 (DCLK1) 
 DCLK1, earlier known as Doublecortin and Calmodulin Kinase Like 1 
(DCAMKL1) is a microtubule-associated protein which is highly expressed in 
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developing brain [42]. Work by Giannakis and colleagues using gene expression 
microarray analysis of small intestinal crypt cells identified DCLK1 as a potential 
stem cell marker [43]. Co-labeling studies with BrdU and DCLK1 demonstrated 
that DCLK1 cells have low BrdU retention and are generally located at the base of 
the crypt. Based on co-staining, Gagliardi and colleagues concluded that DCLK1 
co-localizes with LGR5 (another colon crypt stem cell marker, described below) at 
the base of the crypt and with Chromogranin-A (CgA), a marker for 
enteroendocrine cells, throughout the crypt, further suggesting that DCLK1 can 
mark a specific subset of crypt stem cells specifically in the colon [44]. Work by 
May and colleagues demonstrated that DCLK1 is an epithelial cell surface protein 
and that even though coexpressed with LGR5, DCLK1 is expressed and retained 
more in the quiescent crypt stem cells while LGR5 is expressed more in actively 
dividing stem cell population [45]. Most recently, work done by Nakanishi using 
the Apc
Min/+
: Dclk1
CreERT2/+
 mouse model, showed that in a normal colon, DCLK1 
may be expressed in crypt stem cells but is specifically expressed in tumor stem 
cells and potentially contributes towards maintaining CSC phenotype [46].  
1.4.2.2 Leucin-rich-repeat-containing G-protein-coupled receptor 5 (LGR5) 
 LGR5, earlier known as an orphan G-protein coupled receptor GPR49, was 
identified as a stem cell marker protein identified in intestinal Wnt target gene 
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panel by Baker and colleagues [47]. In addition using the Lgr5
Cre/+
: Rosa2 
lacZ/+
 
mouse model, they showed that these cells are located at the base of the crypt, 
interspersed with Paneth cells and that they can give rise to all the other intestinal 
cell types over the course of time [47, 48]. Lineage tracing studies by Schepers and 
colleagues using a Lgr5
EGFP-Ires-CreERT2
: Apc
fl/fl
 mouse model, suggested that, LGR5+ 
cells constitute 5- 10% cells of the adenomas generated in this model. They also 
demonstrated that these LGR5+ cells are capable of forming adenomas when used 
in a xenograft model [49]. Recently, LGR5 expression was also detected in 
specific cells of the embryonic metanephric mesenchyme cells, a group of cells 
that give rise to adult kidneys. Knock down of LGR5 expression in these cells led 
to improper kidney development [50].  
1.4.2.3 Other putative stem cell markers 
Musashi-1 (Msi-1) is an RNA binding protein identified in neural stem cells of 
Drosophila melanogaster [51]. It is involved in down regulating Notch signaling 
by translational regulation of its target gene Hes-1, that is required for 
differentiation of stem cells into secretory lineage. Msi-1 marks cells located at the 
base of the crypt are interspersed among Paneth cells [52]. Mice lacking Msi-1 
expressing cells, however, do not have defective crypt and intestinal development 
[53].  
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Polycomb complex protein BMI-1 (BMI-1), also known as Polycomb group RING 
finger protein 4 (PCGF4) or RING finger protein 51 (RNF51), plays a critical role 
in maintenance of chromatin silencing [54] and is highly expressed and necessary 
for self-renewal of neuronal, hematopoietic, and leukemic cells. Lineage tracing 
using Bmi-1
Cre/+
mouse model, demonstrated that Bmi-1 expression is found in 
crypt based cells and colocalizes with LGR5+ cells, indicating that Bmi-1 cells 
also mark crypt stem cells [55].  
1.5 Colorectal cancer  
Colorectal cancer (CRC) is the third leading cause of cancer related death in 
United States. Worldwide, up to 5% of all reported cancer cases are due to CRC, 
with 60% of them being diagnosed in industrially developed or developing 
countries.  CRC is caused by genetic and environmental factors. Environmental 
factors ranging from changing dietary habits to environmental toxins are associated 
CRC. In addition, genetic factors such as germline mutations in APC, TP53, and 
DNA mismatch repair genes also contribute to CRC pathogenesis and 
demographically constitute nearly 35% of the registered CRC cases [56]. 
1.5.1 Genetic mutations in colorectal tumorigenesis 
Colorectal tumorigenesis is a multistep process and provides an excellent model of 
study to elucidate the sequential molecular events that lead to cancer initiation and  
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Figure 1.3: Vogelstein Model: According to this model, mutations in the APC 
gene (a critical component of the Wnt pathway) and mis- match repair (MMR) 
pathways are some of the initial events in neoplastic transformation. Following 
this, dysregulation in KRAS-BRAF (Ras/Raf) signaling pathways leads to an 
increase in cell proliferation and adherence free cell growth. Further mutations in 
TP53 gene and activation of PI3K, PTEN, and SMAD pathways would lead to a 
complete neoplastic transformation and development of full-fledged adenoma. 
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progression [57].  The occurrence of CRC is preceded by a sequence of mutation 
events in genes whose normal function would be to maintain chromosomal 
integrity and regulate proliferation. According to “Vogelstein Model” (Fig 1.4), 
colorectal tumors arise as a result of the mutational events, which cause 
inactivation of tumor suppressor genes and simultaneously cause oncogenic 
activation. Mutation in at least four to five tumor suppressor genes is required for 
initiation and formation of a malignant tumor. Fewer mutational events lead to the 
formation of a benign tumor. Most of these mutational events often occur in a 
sequential order in CRC.  It is the accumulation of these mutations that determines 
the biological properties of the tumor [58]. These mutations account for most of 
the chromosomal instability associated with colorectal tumors and lead to loss/ 
mutation of the wild type copy of APC, P53, and SMAD family member 4 
(SMAD4) of tumor suppressor genes whose normal function is to oppose 
malignant phenotype [59] (Fig 1).  
1.5.1.1 Adenomatous polyposis coli (APC) gene mutation   
A variety of signaling pathways play an active role in establishing CRC but clearly 
the Wnt signaling pathway stands out as the prime pathway. As discussed earlier 
(Section 1.3.1 and Fig 1.2), Wnt signaling is critical in establishing a normal crypt 
axis and ensures survival of crypt stem cells. Most of the initial mutational events 
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which lead to colorectal tumors, both in the hereditary form or the spontaneous 
form, occur in genes that code for protein involved in this pathway. A direct 
involvement of the Wnt pathway in colorectal tumors was identified in patients 
with familial adenomatous polyposis (FAP) which a form of inheritable CRC.  
APC is a tumor suppressor gene that is mutated in most FAP patients. Apart from 
serving as a carrier and playing a critical role in regulating cytoplasmic verses 
nuclear level of β-catenin, it also translocates into the nucleus either independently 
or in complex with β-catenin [60].  Recent evidence suggest that APC can regulate 
expression of Wnt target genes by recruiting H3K4 histone demethylase and α-
catenin onto the regulatory regions of these genes [61, 62]. Mutations in APC are 
mostly truncations leading to complete lack of the β-catenin/ axin binding domain. 
This results in increased nuclear translocation of β-catenin and subsequent 
activation of Wnt responsive genes. Multiple intestinal neoplasia (Min) is a mutant 
allele of the murine Apc locus developed using ethylnitrosurea and has high 
penetrance [63]. Like humans with FAP, Apc
Min/+
 mice show extensive 
predisposition to spontaneous intestinal tumors and have been used as models to 
study intestinal tumorigenesis [64, 65]. Taken together, these observations suggest 
that mutations in APC gene serve as the starting point for colorectal cancer 
development. 
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1.5.1.2 Tumor protein p53 (TP53) mutations 
Mutations in the TP53 gene are the second key genetic event in development of 
CRC. TP53 encodes for p53 a tumor suppressor protein which mediates cell-cycle 
arrest, cell death checkpoint, and activates multiple cellular stresses. Most of the 
colorectal adenomas have either a missense mutation or deletion of entire 17p 
chromosomal locus containing the TP53 gene leading to inactivation of one or both 
the alleles of TP53 gene. TP53 mutations cause transition of large adenomas to 
invasive carcinomas [59].  
1.5.1.3 Transforming Growth Factor Beta Receptor Type 2 (TGFBR2) 
mutations 
Somatic mutations in the TGFBR2 are noted in a majority of patients with 
advanced colorectal cancer [66]. The TGFBR2 gene is subject to frameshift 
mutations which occur primarily due to lack of mismatch-repair mechanism in 
advanced CRC. In addition, mutations in the downstream components of the TGF-
β pathway, such as mutations in SMAD genes, lead to high-grade carcinomas [67]. 
1.5.1.4 Mutations in RAS- BRAF and PI3K pathway genes 
Oncogenic mutations in the RAS gene occur in a majority of CRC.  These 
mutations enhance the GTPase activity of the protein rendering it constitutively 
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active. Activated RAS in turn activates the RAF protein by phosphorylation and 
together they activate (via phosphorylate) proteins of the mitogen-activated protein 
kinase (MAPK) signaling pathway to stimulate growth and proliferation [68]. 
Similarly, independent mutations in BRAF alone can activate the serine–threonine 
kinase activity and activate the MAPK signaling cascade. 
BRAF mutations are most commonly detected in small polyps compared to RAS 
mutations, which are more common in hyperplastic polyps, serrated adenomas, and 
proximal colon cancers. Patients with numerous and large hyperplastic lesions, a 
condition called hyperplastic polyposis syndrome, which carry activated RAS-RAF 
mutations, have an increased risk of CRC [69].  
Activating somatic mutations in PI3K-CA, which encodes the catalytic subunit of 
phosphatidylinositol 3-kinase (PI3K), can be detected in advanced cases of CRC. 
The loss of PTEN, an inhibitor of PI3K signaling, is a less common genetic 
alteration and can substitute and augment the effects of PI3K mutations. In 
addition, amplification of the insulin receptor substrate 2 (IRS2), an upstream 
activator of PI3K signaling, along with coamplification of the downstream 
mediators of PI3K signaling component like AKT and PAK4, are also detected in 
advanced colorectal tumors [70, 71]. 
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Figure 1.4: Involvement of growth factors in CRC 
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Figure 1.4: Involvement of growth factors in CRC: Activation of various 
growth signaling pathways plays a critical role in establishment of colorectal 
cancer. COX-2, an inflammation related protein, is upregulated in the initial stages 
of CRC. Subsequent activation of EGFR and TGFBR signaling leads to the 
establishment of tumor. Progressive activation of VEGF signaling induces 
formation of new blood vessels, ensuring tumor survival and aiding metastasis.  
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1.6 Growth factor pathway activation in colorectal cancer 
Numerous growth factor pathways are activated in CRC. These factors directly or 
indirectly influence surrounding tissue environment to help in the growth of the 
tumor and tumor progression (Fig 1.5).  
1.6.1 Prostaglandin E2 
Activation of prostaglandin signaling is an early and critical step in the 
development of an adenoma. Abnormal activation of COX-2 due to inflammation 
or mitogen signaling, mediates the synthesis of prostaglandin E2 (PGE2), an agent 
strongly associated with CRC. 15-prostaglandin dehydrogenase (15-PGDH) is a 
rate-limiting enzyme which catalyzes the degradation of prostaglandin E2. In the 
early stages of CRC, the β-catenin/ T-cell factor-1 (TCF-1) complex binds to and 
inhibits the expression of 15-PGDH leading to complete loss of the enzymatic 
activity and increased accumulation PGE2 and COX-2 in the majority of colorectal 
adenomas and cancers. Clinical trials using non-steroidal anti-inflammatory drugs 
(NSAID), which inhibit COX-2 activity not only prevented development of new 
adenomas but also induced regression of established adenomas [72]. 
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1.6.2 Epidermal Growth Factor Receptor 
Epidermal growth factor (EGF) is a soluble protein that has trophic effects on 
intestinal cells. Clinically, in a subset of colorectal cancer cases, active EGF 
signaling through the EGF receptor (EGFR) has been shown to play a critical role. 
EGF- EGFR signaling activates the MAPK and PI3K signaling cascades. Recent 
clinical data has shown tumor promoting mutations of this pathway. Activating 
mutations in KRAS, BRAF and the p110 subunit of PI3K have been shown in 
advanced colorectal cancer [73]. 
1.6.3 Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF) is an angiogenic factor that is 
responsible for production of new blood vessels, and is produced in states of injury 
and during the growth of normal tissue. Clinically angiogenic signaling pathways 
play a critical role in the growth of colorectal cancer even conferring metastatic 
advantage to the tumor. Anti-VEGF therapy using bevacizumab (an anti-VEGF 
antibody) increased the overall survival of colorectal cancer patients [74].  
Inferring from the above results and clinically speaking, colorectal cancer is a 
result of multifactorial interactions that ultimately manifest into a disease. 
However, the challenge is to determine the factor(s) and understand how these 
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factors initiate the development of the tumor, drive its progression, and determine 
its responsiveness to therapeutic agents. 
1.7 Role of endocrine hormones in colorectal cancer 
Endocrine hormones are synthesized and secreted by specialized cell types in the 
body, released into the blood and are involved in regulating growth, development, 
and differentiation of various tissues in the body. They also play an active role in 
regulating various physiological functions such as growth, metabolism and 
reproduction by modulating specific signaling pathways. Any disruption either in 
the synthesis and production of these hormones or their downstream signaling 
cascade would lead to a disease state. Endocrine hormones particularly PRL, play a 
relevant role in breast, lung, hepatic and prostate cancer. Accumulating evidence 
indicates PRL’s active involvement in colorectal cancer.   
1.8 Prolactin (PRL) 
PRL is a peptide hormone produced and secreted by the lactotrophs of the anterior 
pituitary was initially identified in 1928 by Stricker and Grueter [75]. Later 
experiments by Oscar Riddle in 1933, using the pigeon crop-sac assay, clearly 
elucidated for the first time that this pituitary extract can stimulate milk production 
and named it “Prolactin” [76]. The existence of a distinguishable human 
homologue of PRL was a highly debated issue prior to 1970. Histochemical studies 
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by independent labs identified PRL secreting cells in the pituitary during 
pregnancy. This has provided compelling evidence for the first time for the 
existence of PRL, thus establishing its identity, independent from growth hormone 
[77]. Serum levels of PRL are high in pregnant and lactating women [78] and 
neonates [79].  
In humans, the PRL gene is located on chromosome 6 [80]  spanning a region of 10 
Kb, and it consists of 5 exons coding for a peptide of 227 residues (of which 28 
residues make up the signal peptide) [81]. PRL gene and protein share 
considerably homology with growth hormone (GH) and placental lactogen (PL) 
and are grouped into the same protein family. It is believed that all these genes 
arise from the same ancestral gene through gene duplication and mutation events 
[82, 83]. Several PRL variants have been identified which arise due to 
posttranslational modification and considerably expand the functionality of the 
hormone [84].  
Contributions by Horseman and Ormandy using animal models including mice 
deficient in PRL [85] confirmed that PRL was the hormone responsible for 
lactation. Synthesis and secretion is PRL is a tightly regulated process which is 
multifactorial involving both negative (dopamine) and positive regulators 
(Estrogen, cAMP, Insulin, Thyroid Releasing Hormone). 
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Figure 1.5: Prolactin gene and transcripts: PRL gene is located on chromosome 
6, and codes for two distinct transcripts from two different and independent 
promoters. The pituitary transcript is shorter than the extrapituitary transcript, 
which has an additional exon ‘1a’. However, irrespective of the promoter used or 
the length of the transcript, they both produce the same 23 kDa active PRL protein. 
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Neuroendocrine regulation at the hypothalamic level is regulated by dopamine, and 
contributes to the daily variation in serum PRL levels and the stress induced 
increase in serum PRL [86, 87]. Secretion of pituitary PRL is regulated by a short-
loop feedback regulation. First, synthesis and secretion of pituitary PRL is 
controlled by dopamine, a catecholamine neurotransmitter. Dopamine is produced 
in the hypothalamus and acts through the D2 subclass of dopamine receptors on the 
lactotroph cells of the anterior pituitary to negatively regulate PRL expression and 
secretion [88].  Second, after reaching a threshold serum concentration, active PRL 
signaling through PRL receptor (PRLR) increases dopamine production leading to 
inhibition of PRL [89]. Supportive evidence for the negative feedback effect of 
PRL comes from work by Binart and colleagues who observed increased serum 
PRL levels in Prlr knockout (Prlr
-/-
)mouse models [90, 91]. Several factors such as 
neurotransmitters, neuropeptides and other hormones have also been implicated in 
regulating PRL production [92]. Ectopic production of PRL has also been detected 
in mammary [93], lung [94], bladder [95], uterine decidua [96, 97], prostate and 
ovary tumors [98]. PRL or PRLR transcripts and protein were found to be 
overexpressed in malignant tissue as compared to normal tissue and this increase is 
localized mainly to the epithelial cells. This suggests that epithelial cells are the 
main ectopic source of the peptide hormone [99]. 
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PRL expression is regulated by two distinct promoter elements; a pituitary 
promoter located upstream of the transcription start site is necessary and sufficient 
for transcription of PRL in response to pituitary signals [100]. A second promoter 
regulates extrapituitary expression of PRL and was initially described as directing 
PRL expression in lymphoid and decidual cells [101, 102]. The transcript lengths 
differ depending on the promoter used and the tissue type, but encode identical 23 
kDa (23k PRL), mature peptide. This represents the predominant form synthesized 
and secreted by the pituitary and extra-pituitary tissues (Fig 1.5). In addition, a 
novel N-Terminal 16 kDa (16K PRL) fragment of PRL has been described which 
inhibits angiogenesis by affecting endothelial cell proliferation [103, 104]. 
1.9 Prolactin and its role in normal development and pathologies 
Since its initial identification, the involvement of PRL in regulating normal 
development of various tissues and its role in various growth abnormalities, 
particularly cancer has been a subject of active research. We now know from 
published work over the last decade that PRL and the subsequent signaling induced 
by it regulate not only normal development of various tissues, but also have a 
supportive role in development of various pathologies.  
 
 
36 
 
1.9.1 Role of PRL in brain, stress, fertility and pregnancy 
Apart from circulating PRL being transported to the brain, work done by Fuxe and 
colleagues using PRL specific probes and antibodies showed the existence of PRL 
like transcripts and protein in brain sections of hypophysectomized rat brains 
suggesting that brain produces PRL [105-107]. Similarly, estradiol (E2)-treated 
hypophysectomised rats or direct injection of E2 into the pons-medulla region of 
the brain caused increased PRL expression compared to untreated controls, further 
supporting pituitary independent expression of PRL in brain [108]. PRL is an 
anxiolytic agent capable of inducing a dose-dependent suppression of anxiety 
behavior and acute stress response [109, 110]. Injecting PRL antisense oligos into 
the pituitary portal system prevented anxiety and acute stress response supporting 
the role of PRL as an anti-stress factor [110]. Corticotrophins are released in 
response to acute stress. Chronic PRL treatment blocked stress-induced increases 
in corticotrophin releasing hormone in para-ventricular nucleus thus reducing 
neuronal activation in response to stress [109]. 
Pituitary production of PRL increases during pregnancy and lactation. It is 
necessary for the proper establishment and maintenance of pregnancy. Elevated 
levels of PRL are maintained by the suckling stimulus in the post parturition period 
[111, 112]. Along similar lines, increased immuno-reactive PRLR was observed in 
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brain sections of rats having active and ample sucking stimulus compared to 
control non-pregnant rats, demonstrating increased sensitivity of brain and 
associated neurons to PRL during pregnancy [113]. PRL causes pregnancy induced 
increases in food intake by inducing leptin (a hormone responsible for satiety) 
resistance [114], an adaptation necessary to meet the energy demands of the  
developing fetus and/ or lactation [115]. The anxiolytic effect of PRL suppresses 
stress responses induced by glucocorticoids during late pregnancy, lactation, and 
pregnancy induced hyperthermia an adaption responsible for decreasing fetal 
growth and abnormalities [116, 117]. In addition, PRL-induced transient 
suppression of fertility as adaptation to balance the nutritional need and energy 
expense necessary for lactating females and birth spacing [118]. Finally, PRL-
induced hypothalamic neurogenesis during pregnancy is important in establishing 
maternal recognition of the offspring, contributing to enhancement of maternal 
behavior [119].  
1.9.2 Role of PRL in normal breast development and breast cancer 
PRL is the principal lactogenic hormone secreted by the lactotroph cells of the 
anterior pituitary and is critical in inducing and establishing lactation, milk 
production and milk macronutrient content. The concentration of circulating 
prolactin increases during pregnancy so that by the end of gestation, levels are 10 
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to 20 times over normal non pregnant levels. Acting both as a mitogenic and a 
differentiating agent, PRL profoundly influences the normal development and 
differentiation of the mammary gland. Data obtained using PRL and/or PRLR 
knockout mice show that PRL regulates branching of ductal epithelia during 
puberty and controls lobulo-alveolar development and lactogenesis during 
pregnancy [120]. Elevated levels of progesterone, observed during pregnancy 
prevent pre-parturition PRL induction of milk secretion. Following fetal delivery, 
clearance of progesterone and estrogen releases the inhibitory influence on PRL, 
ensuring copious milk secretion [120]. Experiments on bovine models indicate that 
inhibiting PRL delays mammary gland development and differentiation.  
In differentiated mammary cells of a nursing female, PRL stimulates synthesis and 
secretion of milk protein β-casein, a part from stimulating the synthesis of alpha-
lactalbumin (the regulatory protein of the lactose synthetase enzyme system) and 
increasing lipoprotein lipase activity. Post parturition, PRL ensures continued milk 
production. PRL is also secreted into milk at levels nearly close to the circulating 
concentration, however the physiological significance of this PRL in the infant is 
unknown [121]. 
Evidence supporting the mitogenic role of PRL on mammary epithelia comes from 
studies where PRL was knocked down either in mammary epithelium, stroma, or 
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both. These mice demonstrated normal mammary development until parturition. 
However, a significant decrease in mammary epithelial cell proliferation was 
observed postpartum, as demonstrated by decreased bromodeoxyuridine (BrdU) 
incorporation in the PRL knockouts compared to wild type controls, suggesting the 
involvement of autocrine/paracrine PRL in mammary epithelial cell proliferation 
[122].  
A large number of publications in the early 1970’s indicated a strong association 
between excess PRL in the serum with increased risk of developing breast cancer. 
The role of PRL in mammary cancer was suggested several decades ago, based on 
initial observations in rodent models of breast cancer [123]. Welsch and colleagues 
showed that mammary PRL contributes significantly to the pathogenesis and 
progression of neoplastic mammary tumors in mouse models [124]. Isograft of 
pituitary under the renal capsule in rodent models leads to elevated serum PRL 
levels. Multiple incidences of spontaneous mammary tumors were noted in these 
model suggesting active production of mammary PRL and its involvement in 
mammary tumorigenesis [125]. Oakes and colleagues identified a decrease in 
neoplastic lesions in PRLR knockout mouse [126].  
To demonstrate the autocrine/ paracrine function of PRL in human breast cancer, 
PRL responsive estrogen receptor (ER) negative breast adenocarcinoma cells 
 
40 
 
T47Dco and  ER+ve MCF7 cells were treated in vitro with monoclonal anti-human 
PRL antibodies (mAb 631 and mAb 390). This resulted in 86 and 68% inhibition 
of cell growth in T47Dco cells and 20 and 71% reduction in the MCF7 cells 
respectively as compared to untreated cells implicating the mitogenic effect of 
local PRL in human breast cancer. Additionally, PRL responsive, Nb2 rat 
lymphoma cells, cultured in conditioned medium collected from PRL antibody 
treated T47Dco had decreased growth, as compared to cells cultured in media from 
untreated T47Dco cells, further supporting active secretion and  an autocrine action 
of PRL in these cells [93]. Together, these data suggest that human breast tissue, 
both normal and malignant, is a source of extrapituitary PRL. Not only PRL but 
transcript and protein levels of PRLR were also increased in a vast majority of 
breast cancer biopsies independent of estrogen and progesterone receptor status 
[127, 128].  
1.9.3 Role of PRL in normal prostate development and prostate cancer 
The prostate gland is a hormone-dependent organ. Androgens and PRL plays an 
important role in growth, development, and differentiation of the prostate. Prostate 
cancer (CaP) currently represents the second most common cause of cancer death 
and is the most frequently diagnosed cancer in men [2]. Worldwide 8-103 cases 
per every 100,000 individuals are diagnosed with CaP with a mortality rate of 2-32 
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per 100,000 individuals. In the United States, CaP represents the most frequent 
tumors representing 25% of all new reported male cancer cases occupying the 
second most common cause of male mortality [2].  
In 1955, Grayhack identified that prolactin was necessary for complete prostate 
formation and development, using rat models where PRL secretion was inhibited 
in embryonic stages, leading to abnormal development prostate [129]. Similarly, 
chronic hyperprolactinemia rodent models showed a significant prostate 
enlargement [130]. In vitro PRL treatment caused an increase in survival and 
decreased apoptosis in PC3 prostate cancer cells [131]. Transgenic mice expressing 
PRL in a prostate specific probasin induced model had an expansion/ increase of 
the basal/stem cell compartment in the prostates [132]. Additionally, homozygous 
PRLR knockout mice had a 30- 40% reduction in occurrence of prostrate tumors 
compared to wild type mice when challenged with tumor inducing virus, such as 
SV40T [133]. Clinically, elevated preoperative levels of serum PRL were also 
noted in hypernephroma patients and the levels dramatically decreased after 
surgical removal of the tumor [95]. These observations clearly implicate the 
critical role of PRL not only in prostate development, but also in prostate cancers. 
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1.9.4 Role of PRL in normal liver development and hepatological cancer  
PRL is a potent liver mitogen and circulating levels of PRL increase during 
physiological and pathological liver growth. Clinically, a significant increase in 
serum PRL levels was noted in a cohort of patients with hepatic cirrhosis (27-30 
ng/ml in males and 38-42 ng/ml in females) compared to control subjects. Among 
them, patients with suspected encephalopathy had significantly higher serum PRL 
than others which was significantly correlated with mortality [134]. Intravenous 
PRL injection into mice with  chemically induced hepatic cancer, for six weeks, 
led to hepatomegaly, large tumor like foci along with an increase in hepatic DNA 
synthesis and an increase in liver-to-body weight ratio (LBW), suggesting a 
mitogenic role of PRL in hepatic tumors [135]. An additional, PRL treatment for 
23 weeks lead to further increase in the number of tumor foci [135]. In rodents, 
partial hepatectomy (PH) led to an elevation in serum PRL levels as early as 5-15 
min post operation. Protein kinase C (PKC) signaling is a critical pathway that 
regulates hepatic cell proliferation. A simultaneous increase in nuclear PKC 
activity with increased serum PRL in PH rats suggests active PRL-PKC signaling 
leading to hepatic proliferation post hepatectomy [135]. At a molecular level, PRL 
administration after PH causes an increase in several transcription factors involved 
in hepatic cell proliferation such as AP-1, c-Jun and STAT3 along with liver-
specific differentiation and maintenance of energy metabolism such as CEBPα, 
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HNF-1, HNF-4 and HNF-3 [136]. Further, isolated hepatocytes from lactating rat 
treated with exogenous PRL showed an increase in Src- tyrosine kinase activity 
along with an increase in expression of c-fos, c-jun, and c-src genes, which 
promote proliferation and cell division implicating the critical role of PRL in 
promoting liver growth and regeneration [137]. 
1.9.5 Role of PRL in gynecological cancer  
Serum levels of PRL are elevated in women with ovarian and endometrial tumors 
to variable levels and serves as a strong diagnostic biomarker in these tumors 
[138]. Additionally, an increase in expression of PRLR was observed in tumor 
biopsies from patients with ovarian and endometrial cancer compared to healthy 
tissues. This increase in PRLR may be responsible for the PRL induced increase in 
proliferation, cell survival in ovarian and endometrial cancer. In vitro ovarian 
cancer cells treated with exogenous PRL had a rapid activation of Ras-signaling; a 
critical event which initiates ovarian and endometrial cancer development [139], 
implicating the role of PRL in regulating at least some gynecological cancers. 
1.9.6 Prolactin and its role in normal intestine 
PRL stimulates proliferation of the mucosal cells of the gastrointestinal tract in  the 
lactating rat model [140] suggesting a pregnancy induced  role of PRL in 
regulating growth and proliferation in the gastrointestinal tract. Rodent models 
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where pituitary explants were transplanted into the renal capsule showed cellular 
and mucosal hyperplasia in both jejunum and ileum [141]. Pregnancy-induced PRL 
also increased intestinal specific vitamin D and calcium absorption [142]. PRL 
induces expression of bicarbonate transporter necessary for water and electrolyte 
transport suggesting that PRL is helpful maintaining intestinal ion homeostasis 
[143] [144]. 
1.9.7 Implication of prolactin in colorectal tumors 
Bhatavdekar and colleagues reported high serum concentration of PRL in 
preoperative colorectal cancer patients [145, 146]. Ilan and colleagues also 
observed that in 53% of the patients with colorectal malignancy, there was elevated 
levels of PRL that decreased after surgical removal of the tumor [147]. Conflicting 
data by Baert and colleagues suggested hyperprolactinemia to be a secondary 
effect and that it occurs more common in rectal cancer and do not support the 
hypothesis of ectopic PRL production by colorectal tumors [148]. Similar 
observations were reported by Carlson and colleagues, suggesting that the increase 
in circulating PRL may be a consequence of renal, endocrine and psychiatric 
disorders, medications and/ or a premenopausal situation in patients with colorectal 
neoplasms [149]. 
 
45 
 
Studies by Jan-Michel Otte and colleagues with colon cancer cell lines showed  
that exogenous PRL treatment increased H
3
-thymidine incorporation suggesting a  
mitogenic role of PRL in colorectal cancers [99]. Soroush and colleagues observed 
that 76% of patients with colorectal malignancies had an increase in circulating 
PRL levels and suggested that PRL can be a better prognostic marker than 
carcinoembryonic antigen (CEA), an established colorectal tumor marker, a 
finding further supported by Bhatavdekar [145, 150, 151]. However, a further large 
scale studies on an extended patient population comprising both preoperative and 
postoperative patients is necessary to validate the use of PRL as a valid marker for 
colorectal cancer.  
1.9.8 Role of prolactin in stem cells 
Autocrine/ paracrine PRL has been implicated in promoting proliferation and 
growth of stem cell populations in high grade prostate cancer via the activation of 
Jak/STAT pathway [132, 152]. Inhibiting Jak/STAT activation using prostate 
specific PRL knock down and using competitive PRLR-antagonist, Route and 
colleagues, reported prevention of the expansion of prostate stem cell populations 
[153]. 
PRL has also been indicated to play a critical role in the expansion of the neural 
stem cell population during severe brain injury and pregnancy [154]. Isolated 
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neuronal cells treated with recombinant PRL showed an increase in neurosphere 
formation in vitro by a significant proportion compared to untreated cells. Direct 
infusion of PRL into adult dentate gyrus induces an expansion of precursor cell 
population [155].  
Isolated ovarian cancer cells, treated with exogenous PRL showed an expansion of 
clonogenic population and an increase in adherence free growth indicating that 
PRL-induced expansion of primordial/ stem cell population [139]. These findings 
clearly demonstrate that PRL can regulate organ/ tissue specific stem cell 
population. However, the intracellular signaling modules activated in the presence 
of PRL which can regulate growth and expansions of stem cell population are not 
well characterized. 
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Figure 1.6: Prolactin receptor gene structure 
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Figure 1.6: Prolactin receptor gene structure: Located on chromosome 5 at p13 
locus, prolactin receptor gene codes for a single transcript driven from same 
promoter region. However, alternate transcription leads to the production of 
multiple variants as depicted in the figure. These have deletion of various exons 
and have different stop sites.  
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Figure 1.7: Prolactin receptor isoforms 
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Figure 1.7: Prolactin receptor isoforms: Prolactin receptor (PRLR) is a single 
pass transmembrane protein, consisting of extracellular, transmembrane, and 
intracellular domains. The extracellular domain consists of ligand binding S1 and 
S2 domain with S1 having a higher affinity for the ligand compared to S2 domain. 
The intracellular domain consists of B1, V, B2, X-box and Tail domain. B1 and B2 
interact with Jak proteins that can phosphorylate various domains on the tail 
domain. This phosphorylated tail domain now acts as docking sites for STAT 
proteins, which are responsible for intracellular transduction of the signals. 
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1.10 Prolactin receptor 
PRL signals through PRLR, a high-affinity membrane bound, class I cytokine 
receptor family protein [156]. Located on chromosome 5p13, the PRLR gene 
consists of 10 exons with a single promoter region (Fig 1.6) [128]. Multiple PRLR 
isoforms generated by alternate splicing  have been identified in both normal and 
malignant tissues  (Fig 1.7) [157, 158]. The long form (LF), also called the full 
length (FL) isoform of PRLR, represents the classical type I transmembrane 
protein [159, 160]. The extracellular region is made of 24 amino acids and is 
composed two subdomains, the ligand binding S1 domain and a receptor 
dimerization S2 domain, which also has some residual ligand binding activity. The 
intracellular domain contains five juxtamembrane motifs called Box 1, Variable 
Box (V-Box), Box 2, Extended Box 2 (X-Box) and a tail domain, which are 
conserved across the cytokine receptor superfamily. The function of each of these 
motifs is poorly understood; however, it is suggested that the Box 1 motif is 
involved in interaction and activation of Janus kinase 2 (Jak2) after ligand 
stimulation [161-163]. The C-terminal tyrosine residue interacts with STAT5 [164] 
and SH2-containing protein tyrosine phosphatase (SHP-2) [165]. Considerable 
differences exist in the C terminal region of PRLR between humans and rodents, in 
terms of the number and location of the tyrosine residues and the surrounding 
amino acid residues. Further, posttranslational modifications of PRLR and the need 
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of other accessory proteins to modify PRLR upon receptor dimerization have not 
been well elucidated in rodents.  
The intermediate form of PRLR has a deletion of all coding sequence C terminal to 
the X-Box and has been implicated to mediate cell survival but not cell 
proliferation in transfected cells [166].  ΔS1 has a complete deletion of S1 domain 
in the extracellular region and hence has a decreased affinity to PRL [167]. In 
comparison, the long form of PRLR has a relatively higher affinity for PLR 
compared to other isoforms. PRL binding protein (PRLbp) is a freely circulating 
form of PRLR which has been recently identified in human serum, however, its 
real presence and function are being actively investigated [168]. In vitro, it can 
bind to circulating PRL and prevent its interaction with PRLR thereby suppressing 
PRL signaling. Stoichiometrically, PRLbp can potentially sequester up to 35% of 
circulating PRL, indirectly reducing the amount or PRL available for active 
signaling [168]. PRLR is expressed in all organs and tissues at varying levels. The 
expression of various isoforms is thought to vary with hormonal status, estrous 
cycle, pregnancy, and lactation [156].  
1.10.1 PRLR and its implication in pathologies and cancer 
Evaluating the expression of PRLR in diverse tissues has shown that most of the 
tissues expressed both the long and the short form of the receptor in a tissue 
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specific manner. At a tissue level, muscle, thymus and kidney expressed both 
forms in equal amounts. Ovary, uterus and cerebral cortex, expressed the long 
form, only in the estrous phase, the liver expressed predominantly the short form 
[169]. 
Clinically, more than 50% percent of patients with breast cancer showed a 
significant increase in expression of PRLR [170]. At the transcript level there is a 
difference in expression pattern. Grade-I breast tumors predominantly express the 
LF while the grade-II tumors express higher SF and low levels of LF and grade-III 
tumors express similar amounts of LF and SF [171].  
Multiple fibroadenomas (MFA) are a form of spontaneous benign breast tumors, 
which occurs most frequently in young women. In a cohort of 74 MFA patients 
and 170 control subjects, heterozygous activating mutations leading to substitution 
of isoleucine-146 with leucine (Ile(146)-->Leu) was noted in some of the patients. 
This mutation resulted in a constitutively active form of PRLR, leading to 
increased STAT5 signaling and rapid cell proliferation [172]. In vivo, stable 
overexpression of PRLR in breast cancer cell lines caused an increase in PRL 
signaling leading to increased cell proliferation and tumor formation in xenograft 
models. Knocking down of PRLR led to decreased proliferation and an overall 
reduction of tumor mass [173, 174]. Given the widespread expression of PRLR 
and the corresponding PRL-PRLR signaling in breast cancer, several 
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pharmacological interventions have been developed aimed at targeting PRLR to 
treat breast cancer [175]. LFA102 is a humanized neutralizing monoclonal 
antibody directed against the extracellular domain of PRLR. Nb2-11 rat 
lymphocyte cells, which respond to PRL by increasing proliferation, however, 
when treated with LFA102 they showed a significant decrease in cell division and 
xenograft formation [176]. Clinically, LFA102 is being recommended to patients 
with breast cancer, where it antagonizes PRL signaling leading to reduction of 
tumor load [176].  
1.10.2 PRLR and its implication in gastrointestinal cancer 
The widespread expression of PRLR mRNA along the GI tract and associated 
lymphatic tissue, suggests an active role for PRL in regulating GI immune 
functions [177] and CRC. PRLR transcripts were detected in isolated gastric 
glands, gastric cell fractions, and intestinal mucosa lineages from human, rabbit, as 
well as fetal and adult rat [177]. Human gastric mucosal adenomas, gastrointestinal 
cancer cell lines, and intraepithelial lymphocytes also expressed high levels of 
PRLR.  
1.11 Prolactin Signaling 
Binding of PRL to PRLR triggers an intracellular signaling cascade involving the 
Jak/ STAT pathway, Jak-Ras-Raf-MAPK pathway and/ or the Src tyrosine kinase 
pathway proteins [156, 178]. Site directed mutagenesis studies led to the 
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identification of specific features in the intracellular domain that can be linked to 
activation of specific signaling cascade via the recruitment of STAT proteins, 
insulin receptor substrates (IRS) and other adaptor proteins to the receptor dimer 
with the presence or absence of these features, dictating the activation of a specific 
signaling pathways [165, 179]. PRLR isoforms can also heterodimerize, which is 
important, as PRL target cells usually express more than one PRLR isoform further 
increasing the complexity of signaling associated with PRL.  
PRLR deficient mice have served as a useful model to study the effects of PRL in a 
detailed manner. Mice having germ line deletion of Prlr were produced by 
homologous recombination by Ormandy and colleagues [91]. A detailed analysis 
of these mice was done by Kelly and colleagues who identified that circulating 
PRL levels in these mice were elevated by 30 -100 fold, suggesting a direct 
feedback regulation of PRL expression. Homozygous mutant (Prlr
-/-
) females are 
completely sterile with defects in blastocyst implantation and breast development 
apart from other reproductive tract abnormalities. In hemizygous condition (Prlr
+/-
) 
females exhibited severe, breast development and nursing defects occurred in their 
first pregnancy but recovered in subsequent pregnancies. Homozygous null 
females also exhibited a higher degree of maternal anxiety when challenged with 
foster pups and suffered a general decrease in bone development and density [180]. 
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1.12 JAK-STAT signaling 
Darnell and colleagues identified that interferon-α and γ treatment leads to 
activation of Drosophila melanogaster melanogaster homologue of Jak proteins in 
human cells. Activated Jak in turn lead to the activation of STAT proteins [181, 
182]. This pathway is a pleotropic cascade responsible for transducing multiple 
signals that regulate development, immunity, and homeostasis from flies to 
humans. In higher mammals, such as humans, the Jak-STAT pathway is the 
principle pathway regulating cytokine and growth factor responses that stimulate 
cell proliferation, differentiation, migration and apoptosis, events that are critical 
for hematopoiesis, immune development, mammary gland development, lactation, 
adipogenesis and sexual maturation. Activation mutations in proteins of this 
pathway lead to neoplastic transformation of these tissues. Similarly, dominant 
negative mutations inactivate of these proteins, lead to several early developmental 
defects and embryonic lethality [183, 184] .   
Mechanistically (Fig 1.8), receptors that activate Jak-STAT signaling are normally 
single pass transmembrane receptors for cytokines and growth factors. Binding of 
these ligands to the extracellular domain leads to receptor activation and 
subsequent dimerization. Dimerized receptors serve as docking sites for the Jak 
family of proteins in a region designated as Box1 and 2 domains.  In humans, the 
Jak family has four members: Jak1, Jak2, Jak3 and Tyk2. Receptor bound Jak 
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transphosphorylates multiple other sites on the Jak and the receptor itself. These 
phosphorylated sites on the receptors act as binding sites for STAT proteins [185, 
186]. 
STAT proteins are latent transcriptional factors/initiators that reside in the 
cytoplasm until activated through phosphorylation. Receptor bound STAT proteins 
are phosphorylated by receptor bound Jak proteins at the evolutionary conserved 
C-terminal domain at the tyrosine residue leading to its activation. Activated STAT 
proteins release the receptor and dimerize in the cytoplasm via the conserved SH2 
domain and subsequently translocate into the nucleus, aided by the importin-Ran 
proteins. Once inside the nucleus, STAT proteins bind to the conserved 
sequencesin the enhancer regions of STAT responsive genes. Jak mediated STAT 
activation is sometimes aided by adapter proteins such as STAM (signal 
transducing adapter molecules). STAM1 and 2A are predominant forms in 
humans, which interact with protein phosphatase. These proteins can interact with 
either Jak or STAT proteins and inactivate them through dephosphorylation [187]. 
Apart from binding to STAT proteins, Jak phosphorylated residues on the receptor 
also serve as docking sites for the SH2-domain containing adapter protein complex 
consisting of GRB2, SHP-2 and SHC proteins. This complex of proteins lead to 
subsequent downstream activation of mitogen activated kinase proteins (MAPK). 
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Figure 1.8: Jak- STAT signaling 
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Figure 1.8: JAK- STAT-ERK signaling: This signaling pathway is 
predominantly activated by cytokines and growth factors. Binding of the ligand to 
receptors leads to receptor dimerization. JAK proteins bind to the dimerised 
receptor and get auto phosphorylated and also phosphorylate several tyrosine 
residues on the receptor which act as binding sites for STAT family of proteins. 
These STAT proteins are later phosphorylated by JAK leading to their activation, 
dissociation from the receptor, and dimerization in the cytoplasm. Dimerized 
STAT proteins translocate into the nucleus and bind to respective enhancer 
elements. Additionally, Jak proteins can activate ERK signaling mediated by the 
Grb2-Ras/Raf complex. 
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1.12.1 Role of JAK-STAT signaling in pathologies 
Cytokine signaling plays a critical role in maintaining appropriate immune 
responses and also in several autoimmune diseases. The cytokine activated Jak-
STAT signaling cascade is hyperactivated in autoimmune diseases [188]. Renal 
cancer cell lines treated with cytokines had increased activation of STAT3 leading 
to increased cell proliferation and decrease apoptosis [189]. AG490 mediated Jak 
inhibition causes complete abrogation of STAT activation implicating Jak-STAT 
signaling has a pivotal role in renal cancer progression [189]. 
Pancreatic ductal adenocarcinoma is an aggressive, highly metastatic form of 
pancreatic cancer with hyper active Jak2/ STAT3 signaling pathways that regulate 
both initiation and progression of the disease. Therapeutically, inhibiting both 
these pathways using the JAK2 inhibitor, in cell lines and animal model decreases 
growth, cell proliferation, migration, invasion and increases apoptosis compared to 
untreated cells, implicating the critical role of Jak/STAT signaling in pancreatic 
cancer [190]. 
Bonni and colleagues demonstrated the critical role of Jak-STAT in glial 
differentiation [191]. They showed that Jak-STAT signaling is active in embryonic 
cortical precursor cells and initiated differentiation of these cells into astrocytes, a 
phenomenon augmented by cytokines [192]. Clinically, STAT3 was not active in 
normal brain however, increased levels of STAT3 phosphorylation along with 
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increased expression of STAT3 responsive genes that promote cell cycle 
progression and decrease apoptosis, was observed in brain tumor cell lines. In 
addition, multiple other pathways also seem to converge on STAT3 in brain 
tumors. Further support for this comes from that fact that inhibiting STAT3 alone, 
genetically or pharmacologically leads to a decrease in tumor phenotype, 
implicating the central role of STAT3 in brain tumor pathologies [193]. 
1.12.2 Significance of JAK-STAT signaling in colorectal cancer 
Corvinus and colleagues demonstrated that Jak/STAT signaling apart from Wnt 
signaling plays a significant role in colorectal cancer. Dedifferentiated cancer cells 
and infiltrated lymphocytes of CRC patient samples showed a constitutively active 
STAT3 compared to uninvolved colon epithelium. Isolated CRC cells from these 
patients eventually lost their STAT3 activity. However subsequent implantation of 
these cells into flanks of nude mice led to reactivation of STAT3. Blockade of 
STAT3 activation slowed down the development of CRC derived xenograft tumors 
[194, 195]. Xiong and colleagues showed that either inhibiting JAK activity using 
AG490 and STAT3 expression using specific siRNA, decreased expression of 
genes responsible for cell growth, survival, invasion, and migration such as Bcl-2, 
p21, p27, E-cadherin, VEGF, and MMPs. They also showed that Jak2 is subjected 
to proteasome-mediated proteolysis and dephosphorylation. An increased level of 
nuclear phopho-STAT3 immunostaining was identified in adenomas and 
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adenocarcinomas while phospho-Jak2 immunoreactivity was found in the 
cytoplasm suggesting a positive correlation between Jak-STAT and CRC [196]. 
Adenoviral mediated overexpression of the suppressor of cytokine signaling 
(SOCS3) gene (an inhibitor of the JAK/STAT3 pathway) suppressed CRC cell 
growth and induced apoptosis both in vitro and in vivo, suggesting the critical role 
of JAK-STAT3 pathway in CRC. This action efficiently inhibited the activation of 
this pathway and decreased expression of downstream tumor promoting factors 
[197]. Clinically, genetic variations in JAK1, JAK2, TYK2, SOCS1, SOCS2, 
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6 were 
predominant in patients with colorectal cancer. Among them JAK2, SOCS2, 
STAT1, STAT3, STAT5A, STAT5B, and STAT6 were predominant in patients 
with colon cancer while STAT3, STAT4, STAT6, and TYK2 were associated with 
patients with rectal cancer further implicating that JAK-STAT polymorphism and 
signaling have a critical role in CRC, and may be potential therapeutic targets [195, 
198].  
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Chapter 2: 
 
Prolactin signaling enhances colon cancer stemness by modulating Notch 
signaling via JAK2-STAT3/ERK pathway 
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2.1 Abstract 
Prolactin (PRL) is a secretory cytokine produced by various tissues. Binding of 
PRL to the cognate prolactin receptor (PRLR) activates intracellular signaling via 
Jak, ERK and STAT proteins. PRL regulates diverse activities under normal and 
abnormal conditions including malignancies. Previous clinical data suggest that 
serum PRL levels are elevated in colorectal cancer patients. In this study, the 
expression of PRL and PRLR in colon cancer tissue and cell lines was assessed. 
Higher levels of PRLR expression in the cancers and cell lines were observed 
compared to normal colonic epithelial cells. Incubation of colon cancer cells with 
PRL induced JAK2, STAT3, and ERK1/2 phosphorylation and increased 
expression of Jagged 1 (JAG1), a Notch-1 receptor ligand. The cleaved/ active 
form of Notch-1 receptor (NICD), increased expression of Notch responsive genes 
HEY1, HES1 and stem cell marker genes DCLK1, LGR5, ALDH1 and CD44 were 
all increases in CRC cell lines. Finally, pharmacologically inhibiting the PRL 
induced JAK2-STAT3 and JAK2-ERK1/2 signaling abrogated Notch activation an 
important component of CRC stem cell. Together, the results demonstrate that 
cytokine signaling induced by PRL is active in colorectal cancers and may provide 
a new target for therapeutic targeting. 
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2.2 Introduction 
Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths 
in both economically developed and developing countries. It is the second leading 
cause of cancer deaths in both males and females in United States [2]. The 
precancerous predisposition of colorectal epithelial polyps is no longer disputed.  
There is a plethora of morphologic and molecular studies that carefully analyzed 
the progression of a non-cancerous polyp, into invasive cancerous lesions.  These 
process are complex and influenced by various intrinsic and extrinsic factors such 
as hormones [199]. 
Prolactin (PRL), a cytokine hormone, accumulates in the tissue microenvironment 
and elicits its action in an autocrine and/ or paracrine manners to regulate diverse 
physiological activities that include reproduction, growth, development, 
metabolism, and immunomodulation [93, 120, 200, 201]. Binding of PRL to the 
single pass, transmembrane Prolactin receptor (PRLR) induces several intracellular 
signaling cascades mediated via JAK-STAT [153, 202] and JAK-RAS-MAPK 
components [203].  
PRL acts as a mitogen promoting cell proliferation, inhibiting apoptosis, and 
inducing chemoattraction in breast cancer cells [120, 204, 205]. Blood levels of 
PRL were found elevated in patients with hepatocellular carcinoma [206, 207] and 
ovarian cancer [138]. Cultured immortalized ovarian epithelial cells and 
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endometrial cells treated with exogenous PRL demonstrated increased proliferation 
and inhibition of chemotherapy induced cell death [139]. Autocrine PRL induces 
PRLR-mediated Jak2-STAT signaling in prostate cancer [130, 131, 152, 208] and 
modulates the stem cell/basal cell population [152].  
PRL and PRLR are expressed all along the GI tract in fetal and neonatal stages 
during development [177]. In adult rats, PRL induces active potassium ion 
transport in distal colon and chloride
 
ion transport in proximal and transverse colon 
[209]. IEC-6 colon crypt epithelial cells treated with PRL had increased expression 
of nutrient and mineral transport channel proteins without inducing proliferation 
[210].  Elevated serum levels of PRL have been identified in patients with 
colorectal malignancies [145-147, 150]. In addition, increases in PRL and PRLR 
expression were noted in CRC cell lines and tumor samples [99]. 
Cancer stem cells (CSC) initially identified in hematological disorders as tumor 
initiating cells when isolated and transplanted in NOD-SCID mice [15], are long 
lived, self-renewing population of cells that initiate and sustain tumor growth and 
can be identified by unique set of marker proteins such as DCLK1 [44-46], LGR5 
[47, 48, 50, 211], CD44 [212] and CD133 [23], which also mark normal colon 
stem cells. These cells are resistant to therapeutic interventions and cause tumor 
relapse and metastasis [213, 214]. Identifying cellular factors that regulate the stem 
cell population are critical in understanding the process of neoplastic 
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transformation and for development of novel therapeutics to target the cancer stem 
cell pool. Isolated primary mouse hippocampal cells treated with exogenous PRL 
showed increased number of stem cells [155]. Similarly, in mouse models, 
inducing PRL under the control of prostate specific probasin promoter led to 
expansion in the basal cell compartment [132, 152], which constitutes the stem cell 
population of the prostate gland. Although these data suggest that PRL can affect 
the tissue stem cell population, its effects on cancer stem cells have not been 
determined.  
The Notch signaling pathway is active in intestinal stem cells [215]. It is involved 
in regulating stem cell hierarchy and determining cell fate [24] and is active in the 
intestinal crypts [25]. Constitutive Notch activation is necessary for intestinal stem 
cell maintenance [29] and dysregulation of the pathway has been observed in 
colorectal and other forms of cancer [30]. There are four members in the Notch 
receptor family Notch 1 to Notch 4. Binding of specific ligands like Jagged 1, 2 or 
Delta like 1, 3, 4 to the Notch receptors results in a conformational change in the 
receptor. Subsequent activation of the -secretase complex, composed of 
Presenilin, Nicastrin, Anterior Pharynx Defective 1 (APH 1) and Presenilin 
enhancer 2 (PEN-2) cleaves the Notch receptor to release the intracellular domain 
(NICD) [26, 27]. The NICD then translocates into the nucleus, interacts with co-
factors CSL and MAML, bind to target sequences and activate the transcription of 
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genes such as Hes1, Hey1 and stem cell responsive genes [28] such as c-Myc, all 
of which can be used to assess the degree of Notch signal activation. Interestingly, 
ERK can modulate Notch signaling by regulating the expression of its ligand, 
Jagged 1 [216].  
The current study is aimed at determining the effect of PRL on signaling in colon 
cancer cells. We show that PRL induces JAK2-ERK1/2 mediated activation of 
Notch signaling, leading to an increase in spheroid formation and changes in 
cancer stem cell population. Furthermore, PRL signaling in these cells can be 
suppressed with specific inhibitors of JAK2 and ERK1/2.   
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2.3 Materials and Methods 
2.3.1 Cells 
Colon cancer cell lines HT29, HCT116, SW480, SW620, DLD1 and normal 
intestinal epithelial FHC cells were obtained from ATCC (Manassas, VA). The 
cells are well characterized and have been used by multiple investigators. They 
were cultured in the recommended media supplemented with 10% fetal bovine 
serum (Sigma Aldrich, MO) and 1% antibiotic-antimycotics solution (Mediatech 
Inc, VA) at 37°C in a humidified atmosphere of 5% CO2. The cells were cultured 
in serum free media overnight prior to treatment with PRL (500 ng/ml). Where 
indicated, cells were pre-treated with 50 μM Jak2 inhibitor AG490 or 10 μM 
ERK1/2 inhibitor PD98059 (Selleckchem, TX).  
2.3.2 Spheroid assay  
Cells were seeded at a limiting dilution of 1500 cells/ml (total 2 ml = 3000 cells/ 
well in a 6 well dish) in DMEM supplemented with or without PRL (0-500 ng/ml) 
and inhibitors AG490 or PD98059, in addition to EGF (5 ng/ml), FGF (5 ng/ml), 
heparin (1 μg/ml) and B12 supplements (0.25X) and plated on ultra-low 
attachment plates (BD Biosciences, NY). An important point to note is that the 
amount of growth factors used in the culture conditions were reduced to prevent 
any growth promoting effects by these growth factors which can complicate the 
analyses in order to gain a better idea of the role of prolactin in promoting spheroid 
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formation. Specifically, 1/4
th
 the dose of growth factors (EGF, FGF) was used 
along with, Heparin and B12 supplements recommended by earlier studies [217]. 
The limiting dilution of cells was also determined based on this concentration of 
aggregates that lasts for 8 days. Colosphere formation was assessed after 4 to 6 
days and the number and size of colospheres was determined using Celigo 
(Cyntellect, CA).  
2.3.3 RT- PCR analysis 
Colon cancer cDNA panel with matched adjacent tissue controls was obtained 
from Origene (Rockville, MD). Total RNA from cell lines was isolated using 
Trizol reagent (Invitrogen, Carlsbad, CA) following manufacturer’s instructions. 2 
μg RNA was used to synthesize complimentary DNA using Superscript II reverse 
transcriptase and random hexanucleotide primers (Invitrogen, CA). Individual gene 
expression was quantified using SYBR green reagent (Molecular Probes, OR) and 
specific primers with GAPDH as internal standard. Primers for the PCR include 5`-
GCATATTGCGATCCTGGAAT-3` and 5`-CGTTTGGTTTGCTCCTCAAT-3` 
for PRL, 5`-GGAGCTGGCTGTGGAAGTAA-3` and 5`-
CTCCCACTCAGCTGCTTTCT-3`for PRLR, 5`-
GTGCGGTATATTTCCTCCAA-3` and 5`-GTTCCCGTGAAGCCTTTGT-3` for 
JAG1, 5`-CCTCTCTTCCCTCCGGACT-3` and 5`-
GGTCAGTCACTTAATACAGCTCTCTCT-3` for HES1, 5`- 
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Figure 2.1: Expression of Prolactin and its cognate receptor in colorectal 
cancers 
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Figure 2.1: Expression of Prolactin and its cognate receptor in colorectal 
cancers:  
(A) Real time PCR to evaluate expression of PRLR in colon tumors. Increased 
expression of PRLR is noted in tumor samples compared to adjacent controls. (B) 
Real time PCR for PRL colon tumors. Data suggest no change in expression of 
PRL between tumor samples and adjacent controls. (C) Real time PCR for PRLR 
in colon cancer cell lines compared to normal (FHC cells). Increased PRLR 
expression was observed in all colorectal cancer cell lines. (D) Western blot 
analysis.  There were higher levels of PRLR in colorectal cancer cells when 
compared to FHC cells. (E) Real time PCR for PRL in normal and cancer cell 
lines. PRL mRNA was present in all cell lines. (F) ELISA bases quantification of 
PRL.  
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GCTGGTACCCAGTGCTTTTGAG-3` and 5`-TGCAGGATCTCGGCTTTTTCT-
3` for HEY1, 5`-GGTGAACGTCAAGACCACCT-3` and 5`-
GTCCTGAAGGCACATCACCT-3` for DCLK1, 5`-
AACAGTCCTGTGACTCAACTCAAG-3` and 5`-
TTAGAGACATGGGACAAATGCCAC-3` for LGR5, 5`-
TGTTAGCTGATGCCGACTTG-3` and 5`-TTCTTAGCCCGCTCAACACT-3` 
for ALDH1, 5`-CAGCCTCAAGATCATCAGCA-3` and 5`-
GTCTTCTGGGTGGCAGTGAT-3` for GAPDH. 
2.3.4 Western Blot Analysis and Enzyme-Linked Immunosorbent Assay 
Protein samples were prepared in RIPA buffer (Thermo Scientific, IL).  Following 
quantification using BCA Kit (Thermo Scientific, IL), the lysates were subjected to 
poly acrylamide gene electrophoresis and transferred onto PVDF membrane (EMD 
Millipore, MA). Antibodies for PRLR (ab87992), DCLK1 (ab37994) and LGR5 
(ab119012) were obtained from Abcam (Cambridge, MA), Jagged1 (sc6011), Hes1 
(sc25392), Hey1 (sc28746) and ACTB (sc1616) were obtained from Santa Cruz 
Biotech Inc (Dallas, TX), Nicastrin (A00883), Presenilin1 (A00881), APH1 
(A00884) and Presenilin enhancer protein (PEN2) (A00882) were obtained from 
Millipore (Billerica, MA) and Jak2 (3230S), pJak2 (3776S), STAT3 (4904S), 
pSTAT3 (9131S), Erk1/2 (p42/44) (9102S), pErk1/2 (p-p42/44) (9101S), cMyc  
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Figure 2.2: Prolactin induces Jak2, STAT3 and ERK1/2 phosphorylation  
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Figure 2.2: Prolactin induces Jak2, STAT3 and ERK1/2 phosphorylation: (A, 
B) HCT116 cells were treated with 500ng/ml PRL, and lysates were collected at 
regular intervals and subjected to SDS-PAGE. PRL treatment increased 
phosphorylation of Jak2, STAT3 and ERK1/2, starting at 1 min post treatment and 
lasting for 30 min. (C) STAT3 responsive luciferase plasmid was transfected into 
cells and the luciferase activity analyzed after PRL treatment. Dose- and time- 
dependent increases in luciferase activity were observed following PRL treatment 
as compared to untreated controls (*p<0.05).   
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(5605S), NICD (4380S), CD44 (3570S) and GAPDH (2118S) were obtained from 
Cell Signaling (Boston. MA). Specific proteins were detected using 
chemiluminescence (GE Healthcare, NJ). To determine PRL levels, cells were 
cultured in serum free media and the media was subjected to ELISA according to 
manufacturer’s instructions (Molecular Innovations, MI). Briefly, 100 μl of the 
provided standard and concentrated serum free media collected from cells was 
added into wells pre-coated with PRL antibody in triplicates and allowed to bind 
for 30 minutes at which point the wells were washed and treated sequentially with 
primary antibody and streptavidin-HRP bound secondary antibody. Colorimetric 
quantification after treating with substrate was done at 450 nm.  
2.3.5 Luciferase Assay 
Cells were plated and transfected with either 4XM67 pTK-Luc (Addgene plasmid 
8688) [218] or Hes-1A/B-Luc, a kind gift of Dr. Kimberly Foreman, Loyola 
University, Chicago [219], which encode firefly luciferase gene under the control 
of the minimal thymidine kinase (TK) promoter and four STAT3 (4X STAT3 BS) 
or a single Hes1 (HES1 BS) binding site using Lipofectamine 2000 (Invitrogen, 
NY). Cells were pre-treated with PD98059 (10 μM) and/ or AG490 (50 μM) for 2 
h prior to treating with PRL (500 ng/ml). Renilla luciferase expressing pRL-TK 
plasmid (Clontech, Mountain View, CA) was used as internal control. Luciferase 
levels in the cell lysates were determined using Dual Luciferase Reporter Assay 
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System (Promega Corporation, Madison, WI). 
Figure 2.3: Prolactin induces Jak2, STAT3 and ERK1/2 phosphorylation 
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Figure 2.3: Prolactin induces Jak2, STAT3 and ERK1/2 phosphorylation: (A) 
AG490 or PD98059 treatment alone inhibited Jak2 and STAT3 activation which 
was rescued by PRL treatment. However, the combination of both inhibitors 
completely abrogated Jak2 and STAT3 activation which could not be rescued by 
PRL treatment. (B) Cells treated with PD98059 had decreased ERK activation 
while AG490 enhanced ERK1/2 phosphorylation when treated alone. However, the 
combination of AG490 and PD98059, significantly inhibited ERK activation even 
in presence of PRL. 
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2.3.6 Statistical Analysis 
Data from at least three independent experiments were expressed as the mean ± 
SEM and analyzed by unpaired or paired student’s t-test using GraphPad Prism 5 
(La Jolla, CA). P ≤ 0.05 was considered to be statically significant. 
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Figure 2.4: STAT5 is not induced by PRL 
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Figure 2.4: STAT5 is not induced by PRL: HCT116 colorectal cancer cell line 
has low basal level of STAT5. In these cells, PRL (500 ng/ml) treatment did not 
induce an activation of STAT5. T47D breast cancer cell line has higher basal 
STAT5 and in these cells PRL treatment led to a significant STAT5 
phosphorylation as early as 10 minutes post treatment. 
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2.4 Results 
2.4.1 PRLR but not PRL is upregulated in colon cancer cells 
To determine whether prolactin signaling occurs in colorectal cancer, we first 
analyzed the expression of PRL and PRLR in human colon cancer tissues and cell 
lines. Real time PCR quantification using colorectal cancer patient samples 
indicated a significant increase in PRLR but not PRL transcript levels in the 
cancerous tissue when compared to adjacent normal tissue (Fig 2.1 A, B). A 
similar increase in PRLR mRNA levels and protein was observed in CRC cells 
compared to normal colonic epithelial cells (FHC) (Fig 2.1 C, D). Moreover, no 
difference in expression of PRL mRNA was observed between normal colonic 
FHC cells and CRC cell lines (Fig 2.1 E). Quantification of concentrated culture 
media from the cell lines by ELISA indicatd that all cells secrete PRL; however, 
the amount varies with time and in a cell line specific manner ranging from 2- 80 
pg/ml after 24 h (Fig 2.1 F).  
2.4.2 PRL treatment induces STAT3 and ERK1/2 phosphorylation 
Upregulation of PRLR particularly in CRC compared to normal colonic cells 
suggests a role for the pathway in the pathogenesis of colorectal cancer. Binding of 
PRL to PRLR is known to activate the JAK/STAT and JAK/ERK pathways [153, 
202, 203]. The ERK- MAP kinase pathway is also known to be highly active in 
patients with Familial Adenomatous Polyposis [220]. HCT116 cells were treated 
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with recombinant PRL and western blot analyses were performed for JAK, STAT 
and ERK proteins.  There was an increase in Jak2, STAT3 and ERK1/2 
phosphorylation within a minute of PRL treatment (Fig 2.2 A,B). To validate PRL-
mediated STAT3 activation, we transfected HCT116 and HT29 cells with 4XM67 
pTK-Luc plasmid, which encodes, the firefly luciferase under the control of a 
minimal promoter and four tandem STAT3 binding sites (M67 sites). This 
construct has been previously used to demonstrate STAT3-induced gene 
expression [218]. PRL treatment increased luciferase activity in both cell lines in a 
dose- and time- dependent manner (Fig 2.2 C). Even at 100 ng/ml of PRL, there 
was significant induction in luciferase activity observed even at 1h. Pre-treating the 
cells with AG490, a pharmacological inhibitor of JAK2, prior to PRL treatment, 
led to a decrease in STAT3 and ERK1/2 phosphorylation (Fig 2.3 A,B) even in the 
presence of PRL. However, pretreatment with PD98059 alone led to increased 
STAT3 activation (Fig 2.3 A). Moreover, cells treated with the combination of 
JAK2 and ERK1/2 inhibitors, AG490 and PD98059, resulted in complete 
inhibition of JAK2, ERK1/2 and STAT3 phosphorylation (Fig 2.3 A, B). Together, 
the data suggest that PRL induces JAK2, ERK1/2 and STAT3 phosphorylation in 
colon cancer cells. Given that STAT5 phosphorylation has been shown to be 
significantly upregulated in breast cancer cells in response to PRL [7], we also 
determined the level of STAT5 phosphorylation in the colon cancer cells.  
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Figure 2.5: Prolactin affects colosphere formation 
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Figure 2.5: Prolactin affects colosphere formation: (A) Colon cancer cells were 
grown in specific spheroid media in ultra-low binding plates and treated with 
increasing doses of PRL. After 5 d, the colospheres were photographed and 
counted. (B) A dose-dependent increase in spheroid number was observed with 
statistical significance at 500 and 1000 ng/ml of PRL (*p≤0.05). (C) Similar 
increases in diameter were noted at similar doses (*p≤0.05).  
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However, levels of total STAT5 protein were relatively low in colon cancer cells, 
and no significant changes in phosphorylation of the protein were observed (Fig 
2.4), suggesting that STAT3 may be a key player in PRL:PRLR signaling in colon 
cancer cells.  
2.4.3 PRL induced spheroid formation, is inhibited by JAK2 and ERK 
inhibitors 
Previous studies have demonstrated mitogenic activity for PRL in breast cancers 
[120]. Accordingly, we determined whether PRL affects proliferation of colon 
cancer cells. PRL did not have any effect on proliferation of various colon cancer 
cells (Chapter 4, Fig 4.1). Further confirmation of this was obtained when cells 
were subjected to cell cycle analyses by flow cytometry following propidium 
iodide staining.  
Again, there was no difference in cell cycle progression between PRL-treated and 
control cells (data not shown). These data, taken together suggest that PRL does 
not affect proliferation of CRC cells in vitro. 
We next determined whether PRL affects spheroid formation because previous 
studies have demonstrated that PRL stimulates neurosphere formation when 
hippocampal cells are treated with PRL [155]. Additionally, spheroid formation 
remains the best available functional assay to assess the presence of cancer stem  
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Figure 2.6: Prolactin affects colosphere formation 
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Figure 2.6: Prolactin affects colosphere formation: (A and B) Pre-treatment 
with AG490 and PD98059 alone or in combination led to a significant decrease in 
spheroid formation and number as compared to PRL treatment alone (*p≤0.05).  
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cells in a given cancer cell pool [16, 221]. We treated colon cancer cells HCT116,  
SW480 and HT29 with increasing concentrations of PRL (0-500 ng/ml) and 
allowed the colospheres to form over a period of 6-8 days. There was a dose 
dependent increase in colosphere formation (Fig 2.5 A), with a significant increase 
in both number (Fig 2.5 B) and diameter of spheroid (Fig 2.5 C) in all the three cell 
lines. We also determined the effect of inhibiting JAK-STAT and ERK1/2 
signaling with the two inhibitors AG490 and PD98059. Pre-incubation with the 
inhibitors AG490 and PD 98059, either alone or in combination, abolished 
colospheres formation (Fig 2.5 D,E). Moreover, the inhibitors affected colosphere 
formation in the presence of PRL. There were also fewer numbers of colospheres 
and the size of the spheres was significantly smaller, when compared to cells 
treated with PRL alone. These results suggest that PRL signaling can potentially 
regulate colosphere formation. 
2.4.4 PRL induces expression of colon cancer stem cell marker genes 
Since PRL stimulated colosphere formation, a marker for stem cell-dependent 
growth, we next determined whether PRL affects stem cell related gene. Stem cell 
gene were quantified using  Real-Time PCR and western blot of specific markers 
including DCLK1 [44-46], LGR5 [47, 48, 50, 211], CD44 [212], CD133 [23] and 
ALDH1A1 [38]. Real-time PCR analysis demonstrated that PRL treatment induced 
expression of DCLK1, LGR5  
 
90 
 
Figure 2.6: Prolactin induces stem cell marker protein expression 
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Figure 2.6: Prolactin induces stem cell marker protein expression: CRC cells 
were treated with PRL (500 ng/ml) showed increased levels of (A) DCLK1 (B) 
LGR5 and (C) ALDH1A1 mRNA and (D) protein levels. (E) Treatment with 
either AG490 or PD98059 alone decreased DCLK1 and LGR5 protein levels (lane 
4, 6) compared to PRL treatment samples (lane 2, 3). PRL was able to rescue this 
inhibition (lane 5, 7); however, the combination of both AG490 and PD98059 led 
to complete abrogation of DCLK1 and LGR5 expression even in presence of PRL 
(lane 8).  
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and ALDH1 expression (Fig 2.6 A-C). Further confirmation was obtained by 
western blot analyses which showed that all three proteins  along with CD44 and c-
Myc, an oncogene that plays a predominant role in stemness [222], are upregulated 
compared to untreated controls (Fig 2.6 D). This further demonstrates the 
biological relevance of STAT3 activation by PRL. We also determined whether 
signaling through the JAK-STAT and ERK1/2 pathways affects stem cell marker 
expression. Pre-treatment with AG490 or PD98059 alone caused a decrease in 
expression of DCLK1 and LGR5, which was partially rescued upon PRL treatment 
(Fig 2.6 E). These data further suggest that PRL signaling can modulate the 
expression of colon cancer stem cell maker protein expression.  
2.4.5 PRL affects cancer stem and progenitor cells by inducing Notch 
signaling 
Notch signaling plays a significant role in stem cells, and is a pathway active in 
colon cancer stem cells [24, 29]. Phosphorylated ERK1/2 induces Jagged 1 
(JAG1), a Notch receptor ligand [216]. Binding of JAG1 to the Notch receptor 
causes a conformational change and sequential cleavage by ADAM and -secretase 
complex proteins to release the Notch intracellular domain (NICD), which 
translocates into the nucleus and activates  
expression of target genes [215]. We determined whether PRL treatment affects 
Notch signaling in colon cancer cells by modulating JAG1 expression. Quantitative 
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Real-Time PCR analyses demonstrated increased expression of JAG1 and the 
Notch signaling target gene HEY1 (Fig 2.7 A,B). Western blot analyses further 
confirmed the upregulation of JAG1 and HEY1 (Fig 2.7 C). In addition, there was 
an increase in NICD protein levels, along with increased levels of -secretase 
complex proteins anterior pharynx defective 1 (APH1), Presenilin 1 (PSEN1) and 
Presenilin enhancer (PSENEN) (Fig 2.7 C). To further confirm that Notch 
signaling is activated upon PRL treatment, we transfected HCT116 and HT29 cells 
with a plasmid encoding the luciferase reporter gene under the control of the Hes-1 
promoter.  Following 500 ng/ml PRL treatment, a robust induction in luciferase 
activity was observed in both the cell lines (Fig 2.7 D). These results were also 
confirmed using the specific JAK and ERK inhibitors. Inhibiting either JAK2 or 
ERK1/2 signaling alone using AG490 or PD98059 showed decreased JAG1 
expression, NICD cleavage and expression of HEY1, HES1and PSEN1 proteins 
(Fig 2.7 E). This was partially rescued by PRL. Combined inhibition of both the 
inhibitors lead to a further reduction in JAG1 expression, Notch-1 cleavage 
(NICD) and expression of HEY1, HES1 and PSEN1 (Fig 2.7 E) even in presence 
of PRL, suggesting that PRL can regulate Notch signaling through either JAK2-
STAT3 or JAK2-ERK1/2 pathways. 
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Figure 2.7: Prolactin treatment activates Notch signaling  
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Figure 2.7: Prolactin treatment activates Notch signaling:  (A) Real-Time PCR 
analysis of cells treated with PRL show a time dependent increase in expression of 
JAG1 (*p<0.05).  (B) Similar increase in expression of Notch target gene HEY1 
was also observed in Real-Time PCR analysis (*p<0.05). (C) Lysates of PRL 
treated cells showed increased JAG1 and HEY1 expression, NICD accumulation 
and induction of -secretase complex proteins APH1, PSEN1 and PSENEN 
expression as compared to controls. (D) Colon cancer cells, transfected with HES1 
responsive luciferase plasmid showed a PRL dependent induction of luciferase 
activity. (E) AG490 and PD98059 pre-treatment (lanes 4-7) caused a decrease in 
NICD accumulation and JAG1, HEY1, HES1 and PSEN1 expression compared to 
PRL treatment. PRL was able to rescue this activation; however, the combination 
of both AG490 and PD98059 (lane 8) led to complete abrogation of NICD 
accumulation and HEY1, HES1 and PSEN1 expression to levels similar to control. 
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2.4.6 Notch signaling is necessary to mediate PRL induced changes  
Based on the above findings, we hypothesized that PRL induces JAK2-STAT3 and 
JAK2-ERK1/2 cascades that in turn activate JAG1 mediated Notch signaling. To 
evaluate this, we overexpressed NICD in the three colon cancer cell lines. NICD 
overexpression significantly induced colosphere formation, similar to that observed 
when cells were treated with PRL (Fig 2.8 A). There was an increase in the number 
and size of the spheroids (Fig 2.8 B, C). Furthermore, treatment with the inhibitors 
alone did not affect the number or size of spheroids in the presence of NICD 
overexpression. However, a small decrease was observed in secondary spheroids 
when treated with the combination of the two inhibitors (Fig 2.8 D). Similarly, 
protein levels of DCLK1, LGR5 or CD44 increased in NICD overexpressing cells 
to levels comparable to PRL treated cells (Fig 2.8 E). The two inhibitors either 
alone or in combination did not affect expression of stem cells markers in the 
NICD overexpressing cells further suggesting that PRL-induced activation of 
Notch signaling is sufficient to enhance stem cell activity.  
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Figure 2.8: NICD overexpression recapitulates loss of PRL signaling  
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Figure 2.8: NICD overexpression recapitulates PRL-induced changes in 
colosphere formation and stem cell marker protein expression: (A) Colon 
cancer cells were transfected with NICD overexpressing plasmid, grown in specific 
spheroid media in low adherent plates for 5 d in the presence of PRL and 
inhibitors. Neither AG490 nor PD98059 treatment alone or in combination caused 
any significant decrease in colosphere formation in NICD expressing cells. (B) 
Significant increase in spheroid number was observed in NICD expressing cells 
compared to untreated controls. The inhibitors did not affect the NICD 
overexpressing cells (*p≤0.005). (C) Increased colosphere diameter was also 
observed in NICD overexpressing cells compared to control (*p≤0.05). (D) 
Secondary spheroids. The primary spheroids were collected, trypsinised and 
replated without PRL or the inhibitors. PRL primed and NICD expressing cells 
treated with either inhibitor maintained high colosphere formation compared to 
control. Combination of the inhibitors had comparable decrease in spheroid 
number compared to PRL treated or NICD expressing cells. (E) Lysates from 
NICD overexpressing cells either alone or treated with the inhibitors alone or in 
combination had increased expression of cancer stem cell markers DCLK1, LGR5 
and CD44. However, expression of PSEN1 and PEN2 was not affected in NICD 
expressing cells as compared to PRL-treated cells. 
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2.5 Discussion 
Our findings implicate an increase in PRLR transcript in CRC samples compared 
to adjacent normal tissue. Similarly, CRC cell lines had increased PRLR levels 
compared to normal FHC cells. In line with earlier observations [223], SW480 
cells expressed relatively lower PRLR levels compared to other cell lines. No 
significant change in mRNA expression or robust secretion of PRL into the media 
was noted in CRC cell lines compared to FHC. These findings clearly show a 
preferential upregulation of PRLR in CRC cells suggesting a role for PRL-PRLR 
signaling in colorectal tumors.  
Binding of PRL to prolactin receptor (PRLR) activates JAK/STAT and/or RAS-
RAF-ERK1/2 pathway [156, 178]. In fact, we observed a rapid and robust increase 
in STAT3 phosphorylation. We also observed an increase in STAT3 
phosphorylation when treated with PD98059, a similar finding reported earlier 
[224].  In their studies, the authors demonstrated that treating the melanoma cell 
line LU1205 with only PD98059 induces robust phosphorylation of STAT3 and 
STAT5 [224]. Previous studies in breast cancers have also demonstrated STAT5 
activation and not STAT3 activation in the presence of PRL. More importantly, in 
breast cancers it was determined that STAT5 and STAT3 mediate opposing effects 
on several key target genes such as BCL6, with STAT5 exerting a dominant role.  
When both STAT3 and STAT5 are activated at the same time, there is in fact a 
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reduction in the proliferation of the breast cancer cells. Moreover, there was and 
increased sensitivity to chemotherapeutic drugs [225, 226]. In our studies, we 
observed that PRL did not affect the proliferation of CRC cells. The fact that only 
STAT3 is activated in CRC cells suggests differential activity for PRL that 
depends on the cancer type. It might be interesting to overexpress STAT5 in CRCs 
and determine whether PRL treatment would mimic the reduction in proliferation 
as observed in breast cancer.  
The spheroid formation assay helps us determine the presence of cancer initiating 
cells in a cancer cell population [16, 221]. Our results show a dose dependent 
increase in spheroid formation, number and diameter in CRC cells following PRL 
treatment. This is in agreement with previous studies with prostate cancers where 
PRL expression in mouse prostate led to increase in stem cell/basal cell population 
[132, 152]. Similarly, neurosphere formation along with expansion of hippocampal 
precursor cell population [155] has been observed in a PRL dependent manner.  
We also observed increased expression of DCLK1, LGR5, ALDH1 and CD44. 
However, there were differences seen in the stemness based on cell lines. HT29 
cells expressed only moderately higher levels of the marker proteins when 
compared to HCT116. This is also in line with studies of PRL effects on neural 
stem cells [155]. It would be interesting to determine whether expression of stem 
cell related proteins is affected in neural stem cells, and whether this expression is 
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affected in brain tumors.  
PRL also induced Notch signaling via the JAK2-ERK1/2 pathway by inducing 
JAG1 expression leading to NICD accumulation along with an increase in 
expression of Notch target genes. This is of high significance because clinically 
increased ERK1/2 activation was noted in patients with familial adenomatous 
polyposis [220]. Moreover, previous studies have also demonstrated that ERK1/2 
can modulate Notch signaling by regulating the expression of its ligand JAG1 
[216]. Notch signaling is active in intestinal crypts [25] and helps regulate stem 
cell hierarchy and to determine cell fate [24]. Dysregulation in this pathway can 
lead in colorectal cancer [30, 31]. It would be interesting to determine whether 
PRL upregulation is essential for tumorigenesis.  
Based on our observation, we put forward a model where the presence of PRL in 
the tumor microenvironment of CRC cells would activate JAK2 after binding to 
PRLR, which would in turn induce ERK1/2 phosphorylation. Activated ERK1/2 
would induce JAG1 expression in the cells which would translocate to the cell 
membrane. Binding of JAG1 extracellular domain to the single pass 
transmembrane Notch-1 receptor would lead to intracellular conformational 
changes and cleavage by the -secretase complex proteins leading to separation of 
the NICD from the transmembrane domain. The cleaved NICD would then 
translocate to the nucleus and complex with Mastermind-like (MAML) and CSL to 
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induce respective gene expression (Fig 2.9). However, it is important to note that 
PRL expression itself is not upregulated in the cancer tissues, but rather only 
PRLR. However, previous studies have demonstrated increased levels of PRL in 
the blood stream of patients with CRC [145, 146]. This suggests that PRL 
expression is induced at other sites. This is also different from what has been 
observed in breast cancers where the cancer tissue itself induces PRL expression 
[93, 152]. It would be interesting to determine how and where PRL expression is 
induced in colon tumorigenesis. In this regard, it should be noted that PRL is 
believed to be a hormone whose expression is responsive to stress. PRL does 
increase in response to psychosocial stress, although women may have higher 
magnitude of increase than men, and this might be dependent on estradiol levels 
(62). Moreover, dietary fat was shown to induce circulating PRL under conditions 
of either stress, and dietary fat can also affect tumorigenesis [227].  
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Figure 2.9: Proposed model of PRL signaling in CRC: Prolactin present in the 
tumor microenvironment would bind to PRLR and induce Jak2-ERK1/2 
phosphorylation. The activated ERK1/2 induces expression of Jagged 1 (JAG1), a 
Notch-1 ligand. JAG1 would translocate to the cell membrane and bind to the 
transmembrane Notch receptor in the neighboring cell. This binding would induce 
a conformational change in the receptor leading to sequential cleavages by various 
enzymes including the -secretase complex in the neighboring cell. This results in 
the release of the Notch intracellular domain (NICD) that then translocates into the 
nucleus, complexes with Mastermind-like (MAML) and CBF1/ suppressor of 
hairless-1 (CSL) to activate target gene expression.  
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Chapter 3: 
Heterogeneity in expression of Prolactin receptor in colorectal cancer 
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3.1 Abstract 
Prolactin receptor (PRLR) is a single pass transmembrane protein that activates 
proliferative and growth responses upon interacting with its ligand Prolactin 
(PRL). Overexpression of PRLR was reported in several cancers with higher 
incidences particularly in breast cancer. Our study illustrates a significant increase 
in expression of PRLR in colorectal cancer patient samples and cell lines compared 
to adjacent normal tissue or cells. In addition, we observed a stage specific increase 
in expression of PRLR in patient samples with adenomas and carcinomas having 
high expression while it is low in polyps and inflammation. In silico analysis for 
expression and copy number variation on data retrieved form The Cancer Genome 
Atlas (TCGA) data base pertaining to colorectal cancer patients suggest both an 
increase in expression and copy number of genes in the 5q13 chromosomal locus. 
This locus harbors the PRLR gene along with other genes which may play a critical 
role in colorectal cancer. Sterol response element binding protein 1 (SREBP1) is a 
transcription enhancer and is upregulated in colorectal cancer. It has binding 
regions in the PRLR promoter regions and can regulate its expression in colorectal 
cancer cells. Taken together, our observations indicate that there is a stage specific 
upregulation of PRLR in colorectal cancer and that this upregulation may be a 
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contribution of locus amplification and/ or increase in gene expression due to 
enhanced transcription.   
3.2 Introduction 
Cytokines present in the tumor microenvironment play a critical role in tumor 
progression and metastasis. Upregulation of several cytokines and their receptors 
have been noted in several cancer types. Cancer cells respond to host-derived 
cytokines by increasing cell proliferation, attenuating apoptosis, and increasing the 
invasion and metastasis phenotype. A more detailed understanding of cytokine-
tumor cell interactions provides new opportunities for improving cancer 
immunotherapy [228, 229].  Cytokines interact with specific receptors which are 
transmembrane proteins. This interaction leads to dimerization of the receptors. 
These dimerised receptors can activate several intracellular signaling proteins/ 
cascades that promote cell growth or death.  
Several clinical observations and experimental studies indicated an increase in 
cytokine receptor expression in breast, prostate, ovarian, and endometrial cancers. 
Analysis on a cohort of seventeen breast cancer tissues and adjacent normal tissue 
revealed that growth hormone receptor (GHR) and progesterone receptor (PR), 
showed a significant increase, suggesting that growth hormone (GH) and 
progesterone (P4) may be acting together to promote breast cancer development 
[230]. However, tumor grade (MIB-1 index) and GHR have an inverse correlation 
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indicating that GHR and PR may serve as early prognostic marker [230]. A similar 
increase in expression of GHR, EGFR, keratinocyte growth factor receptor 
(KGFR), in addition to receptors for several colony stimulating factors, was 
observed in inflammatory bowel disease (IBD) [231].  
DNA copy number variations (CNVs) constitute an important component of 
genetic variation. Since their advent, they have been identified in a variety of 
conditions implicating their role in susceptibility to a wide spectrum of 
pathologies. In addition, somatic CNVs can be used to identify regions of the 
genome involved in these disease phenotypes [232]. CNVs occurring in a specific 
gene or affecting the whole chromosomes have been identified to cause various 
pathologies and developmental abnormalities as well as act as a source for genetic 
diversification, adaptation and evolution [232]. CNVs occurring in many genes 
simultaneously can be very detrimental. Compared to higher organisms, CNVs are 
beneficial, increasing survival under selective pressure and augmenting drug 
resistance in microorganisms [233]. Until recently, the significance of CNVs in 
cancer was underappreciated. However, in vitro and clinical studies have 
characterized genomic instability while chromosomal structural dynamism was 
observed in a plethora of cancer types, leading to the conclusion that these genetic 
variations form an important part of cancer pathogenesis [232]. 
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Human epidermoid carcinoma cells A431 have high levels of EGFR. The EGFR 
gene is located on short arm of chromosome 7 and cytological studies have 
identified that this locus is duplicated/ amplified in epidermoid carcinomas. This 
correlates with increased EGFR expression [234]. Similarly, chromosomal band 
analysis on  human pancreatic cancer cell lines T3M4, PANC-1, COLO 357, and 
UACC-462, suggested structural alterations of chromosome 7p in T3M4, PANC-1, 
and COLO 357 cells, while UACC-462 showed multiple copies of chromosome 7 
[235, 236]. Amplification of 20q12-13 chromosomal region encompassing genes 
coding for AIB1, PTPN1, MYBL2, BTAK and ZNF217 is common in breast cancer 
and in ovarian tumors. Clinical studies done on 24 sporadic, 3 familial and 4 
hereditary ovarian carcinomas and in 8 ovarian cancer cell lines showed 
amplification of at least one of the five regions of 20q12-13.2 chromosomal locus 
in 54% of sporadic and 100% of hereditary tumors. AIB1 and PTPN1 genes were 
preferentially amplified in sporadic ovarian tumors while BTAK, MYBL2 and 
ZNF217 gene locus were preferentially amplified in sporadic breast tumors. Such 
high frequency of gene amplification at 20q12-q13.2 suggests that the genes 
present in this region may play a central role in the pathogenesis of ovarian and 
breast cancers [237]. CNV of 1q21-23, 2p12-16, 8q24, 9q34, 12q12-14, 13q32, 
16p12, 18q21-22, and 22q12 locus identified in  large B-cell lymphomas (DLBL) 
demonstrates the significance of genes located in this region in lymphoma-genesis 
 
110 
 
[238]. Oral squamous cell carcinomas often possess a triploid karyotype which is 
associated with disease severity and drug resistance [239]. As regards GI-related 
cancer, amplification of  ERBB2 gene was identified in MKN-7 gastric cancer cell 
line [240]. Apart from amplification, deletion of a locus or the complete 
chromosome can also confer selective advantage. For example, haploinsuffecieny 
of BRCA1 in breast cancer leads to increase in GHR and PR leading to an increase 
in cell survival [241]. 
 In addition to the a forth mentioned genetic changes which can contribute to the 
increase in gene expression, an increase in binding of transcription enhancing 
factors to the enhancer regions of the PRLR gene can also lead to increase in PRLR 
expression at a transcription level.  
Aberrant increase in lipogenesis is a metabolic feature of proliferating tumor cells. 
Normal cells, acquire their fatty acid stock from the circulation: however, in tumor 
cells there is an active de novo synthesis of lipids. Sterol regulatory element-
binding proteins (SREBP), also referred to as sterol regulatory element-binding 
transcription factor (SREBF) encoded by the SREBF genes in humans, is a member 
of the basic helix-loop-helix-leucine zipper (bHLH-Zip) transcription factor family 
of proteins [242], and is a master regulator of lipogenic gene expression. SREBP-
1a, SREBP-1c, and SREBP-2 are the three isoforms of SREBP proteins.  SREBP-
1a and SREBP-1c are transcribed from the same SREBP-1 gene, but from two 
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distinct promoters, while SREBP-2 is encoded by SREBP-2 gene as a single 
mRNA. The relative levels of SREBP-1a and -1c mRNA vary depending on the 
tissue type. SREBP-1c is the predominant isoform in adult liver and adipocytes, 
while, SREBP-1a is predominant in spleen and in cancer cells. 
SREBP-1a interacts with co-activators such as p300/CREB-binding protein and 
Sp1 to regulate transcription. SREPB proteins bind to a highly conserved sequence 
called sterol regulatory element-1 (SRE1) in the promoter upstream regions of 
target genes. SREBP-1a and 1c are potent transcription activators of genes that 
mediate synthesis of cholesterol, fatty acids, and triglycerides, while SREBP-2 
preferentially activates cholesterol synthesis genes [243]. SREBP-1 mRNA is 
translated as a precursor which attaches to the nuclear membrane and endoplasmic 
reticulum. Following activation and cleavage, the mature protein translocates to the 
nucleus and activates transcription by binding to the SRE1. Sterols inhibit the 
cleavage of the precursor, and the mature nuclear form is rapidly catabolized, 
thereby reducing transcription [244, 245].   
Small molecule mediated inhibition of fatty acid synthesis in the HCT116 CRC 
cell line resulted in a dramatic increase in SREBP-1 protein levels [246]. Similarly 
SW480 and SW620 CRC cells treated with oridonin, a potent antiproliferative 
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diterpenoid agent, isolated from Rabdosia rubescens, caused a dramatic decrease 
in SREBP-1 levels resulting from decreased fatty acid synthesis [247].   
Earlier, we have demonstrated that PRL treatment activates the stem cell 
population in CRC. In humans PRL specifically binds specifically to PRLR to 
activate intracellular signaling events [248]. We have shown that an increase in 
expression of PRLR was observed in CRC patient samples and cell lines compared 
to adjacent normal tissue or normal intestinal epithelial cell line. However, the 
reason for this upregulation is not yet known. This work is directed towards 
identifying the expression pattern of PRLR and the molecular basis for its 
upregulation in CRC. 
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3.3 Materials and Methods 
3.3.1 Cell lines 
Well characterized colon cancer cell lines used in the study were obtained from 
ATCC (Manassas, VA). These cells were cultured in DMEM media supplemented 
with 10% fetal bovine serum (Sigma Aldrich, MO) and 1% antibiotic-antimycotics 
solution (Mediatech Inc, VA) at 37°C in a humidified atmosphere of 5% CO2.  
3.3.2 RT-PCR Analysis 
Total cDNA from various sites along the normal human gastrointestinal tract was 
obtained from Clontech (Clontech, CA). Colon cancer cDNA panel with matched 
adjacent tissue controls was obtained from Origene (Rockville, MD). Trizol 
reagent (Invitrogen, Carlsbad, CA) was used to isolate total RNA from cell lines 
following manufacturer’s instructions. 2 μg RNA was used for cDNA synthesis 
using Superscript II reverse transcriptase and random hexanucleotide primers 
(Invitrogen, CA). PRLR expression was quantified using SYBR green reagent 
(Molecular Probes, OR) and specific primers with GAPDH as internal standard. 
Primers for the PCR include 5`-GGAGCTGGCTGTGGAAGTAA-3` and 5`-
CTCCCACTCAGCTGCTTTCT-3`for PRLR, 5`-
CAGCCTCAAGATCATCAGCA-3` and 5`-GTCTTCTGGGTGGCAGTGAT-3` 
for GAPDH, 5`-CTGCTGTCCACAAAAGCAAA -3` and 5`-
GGTCAGTGTGTCCTCCACCT-3` for SREBP-1, 5`- 
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GCTACCTGTCCGGCTACATC-3` and 5`-CGATGCCCATAATGTTGTTG-3` 
for NR2F1/ COUP-TF1, 5`-CCAGGCACCATGCTAGGTAT-3` and 5`-
GTAAGAACAGACCCAGCCACTT-3` for GFI1. 
3.3.3 Western Blot Analysis 
Protein samples were extracted using RIPA buffer (Thermo Scientific, IL) 
supplemented with protease and phosphatase inhibitors. 10-30 μg of protein was 
subjected to poly acrylamide gene electrophoresis and transferred onto PVDF 
membrane (EMD Millipore, MA) following quantification using BCA Kit 
(Thermo Scientific, IL). Antibodies for PRLR (sc-377098), SREBP-1 (sc-365513) 
and ACTB (sc-1616) were obtained from Santa Cruz Biotech Inc. (Dallas, TX). 
Proteins were detected using chemiluminescence (GE Healthcare, NJ).  
3.3.4 Histology 
Tissue microarray slides containing colorectal cancer, adjacent normal, liver and 
lymph node metastatic and normal samples (CO702) and colon adenocarcinoma, 
mucinous, papillary, squamous cell carcinoma of different grades and normal 
colon tissue (CO802) were obtained from Biomax (Rockville, MD). The tissue 
sections were fixed in 1% formaldehyde, following de-waxing at 60
o 
C. Following 
sequential hydration and blocking, the sections were incubated overnight with 
PRLR antibody. Staining was developed using the Histostain kit (Invitrogen, CA) 
following manufacturers protocol. Staining was scored using Clarient Automated 
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Cellular Imaging System (ACIS) (San Juan Capistrano, CA) as previously 
described [249] and the scores obtained were used for further analysis. 
3.3.5 ChIP Assay  
ChIP assay was performed based on protocol from Dr. Jeffery Rosen’s lab 
(https://www.bcm.edu/rosenlab/index.cfm?PMID=13002) with little modification. 
Briefly, HCT116 and DLD1 cells were plated at a confluence of 2 X10
6
 in 100mm 
dishes and were grown to 90% confluence, at which point the cells were cross-
linked by adding 4% formaldehyde (Cat # 433284, Sigma, St. Louis, MO) directly 
into the media to a final concentration of 1%. Fixing was stopped by adding 
glycine to a final concentration of 125 mM. The cells were washed in ice cold PBS 
and cells were scraped and collected. Cell were lysed using a mild buffer (5mm 
PIPES in KOH (pH 8.0), 85mM KCl and 0.5% NP-40, supplemented with protease 
and phosphatase inhibitor) and dounced (Type B) repeatedly to ensure thorough 
cytoplasmic lysis as seen under a microscope. The nucleus was pelleted by 
centrifuging (5000 rpm for 5 min) and suspended in nuclear lysis buffer (50 mM 
Tris (pH 8.1), 10 mM EDTA and 1% SDS supplemented with protease/ 
phosphatase inhibitors) and sonicated to obtain DNA fragments of 0.3- 1 kb size. 
The chromatin was diluted 1:5 in ChIP dilution buffer (0.01% SDS, 1.1% Triton 
X-100, 1 mM EDTA, 16.7 mM Tris (pH 8.1), 167 mM NaCl supplemented with 
protease inhibitors) and pre-cleared using salmon sperm DNA treated protein A 
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agarose slurry. A part of the pre-cleared lysate was saved to be used as input and 
the remainder was mixed with 5-8 μg of SPREBP-1 antibody and following an 
overnight incubation, the antibody/DNA complex was precipitated using salmon 
sperm DNA/ protein A agarose slurry. Reverse crosslinking and DNA extraction 
was followed by semi-quantative PCR using primers specific to upstream region of 
PRLR gene: 5`- GAACTTCAAGAGGAGGAAGT-3` and 5`- 
CCTACAACTTCTACATCTTCTT-3` which produce a 415bp fragment and 5`-
CCTGCATTAGAAGCTCTGCAA-3` and 5`-CTTCCCTCTCAGTGCCTTAA-3` 
that produce a 114 bp fragment.  
3.3.6 Analysis of TCGA Data Sets 
The Z-score values for gene expression and the log2 ratios for copy number 
variations for each of the five genes PRLR, AGXT2, RAD1 and DNAJC21 were 
obtained for 156 patients from TCGA portal (http://tcga-data.nci.nih.gov/ 
tcga/tcgaHome2.jsp) with the collaboration of Dr. Andrew Godwin. Samples with 
a tumor/normal expression level of more than or equal to 0.5 were considered up-
regulated. Samples showing a tumor/normal log2 values of >0.3 for CNV were 
considered to possess a copy number gain [250]. Correlation and regression 
analysis was used to analyze the data. 
3.3.7 Statistical Analysis 
GraphPad Prism 5 (La Jolla, CA) was used to perform all the descriptive statistics 
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including mean, standard deviation and student’s t-test. Data from at least three 
independent experiments were expressed as the mean ± SEM. P value ≤ 0.05 were 
considered significant. 
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3.4 Results 
3.4.1 Expression of PRLR along the gastrointestinal tract 
We first determined the expression of PRLR along the GI tract to get a better idea 
about the expression pattern. Specific primers were designed to detect the full 
length and dSF1 isoforms (together called long form) or the SF1a, SF1b and the 
d7/11 isoforms (short form) (Fig 3.1A and B).  Real-Time PCR data suggests that 
both PRLR long and short forms are differentially expressed along the length of 
the GI tract with the long form being the predominant isoform. Ileocecum, colon 
and liver have higher long form expression compared to other sites, with colon 
having the highest expression (Fig 3.2 A). While the expression of long form is 
predominant in the intestinal portion of the GI tract, short form expression is 
spread throughout, with detectable expression all the way from stomach to rectum, 
and the liver (Fig 3.2 B).    
3.4.2 Expression of PRLR in CRC and normal tissues 
Next, we evaluated the expression of PRLR in CRC and adjacent normal human 
tissues using the same primer pairs. We noted that there was a three-fold increase 
in expression of the long form and a four - fold increase in short form (Fig 3.3 A 
and B) in the tumor samples compared to adjacent normal tissue. However, there 
was a considerable variation in the expression of short form ranging from one to 
five fold increase (Fig 3.3 B). On the other hand, the expression pattern for the  
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Figure 3.1: PRLR transcript grouping and primer binding sites 
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Figure 3.1: PRLR transcript grouping and primer binding sites: For the ease 
of desigiing primers, PRLR transcripts were catagorized into two groups. (A) The 
long form including the full length and the dSF1 isoforms and the (B) short form 
including the SF1a, SF1b and the d7/11 isoforms. For the long form, primers were 
designed spanning exon 9-10, while that for the short form were designed spanning 
only exon 10, but the binding site for the reverse primer is very unique for the short 
form. 
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Figure 3.2: Expression of PRLR along the GI tract 
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Figure 3.2: Expression of PRLR along the GI tract: Evaluation of PRLR across 
the GI tract indicate that both the long (A) and the short (B) form are expressed at 
varying levels across the GI tract with the long form predominantly in the intestine 
and short form more generally expressed. Expression of long form is more 
prominent in the colon as compared to other intestinal sites. Placental tissue was 
used as experimental controls. 
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Figure 3.3: Expression of PRLR in patient samples from CRC and adjacent 
normal tissue 
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Figure 3.3: Expression of PRLR in patient samples from CRC and adjacent 
normal tissue: In general, a significant overall increase in expression of both the 
isoforms of PRLR is observed in CRC tumor samples compared to adjacent normal 
tissue samples. (A) While the expression of the long form is more compact and 
significant, (B) short form expression is more variable among both the normal and 
maligant samples.  
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long form was tighter with most of tumor samples showing a significant increase in 
expression as compared to adjacent normal samples (Fig 3.3 A). 
3.4.3 Histological validation of PRLR expression in CRC and normal tissues 
We next used immunohistological studies to further validate the increase in PRLR 
expression. CRC samples and normal tissue sections were stained with PRLR 
antibody which detects  the C-terminal region of PRLR receptor and scored for 
intensity. Detectable levels of PRLR was noted along the crypt length in normal 
colon (Fig 3.4 A, B), predominantly in the membrane of  the epithelial cells lining 
the crypt and a few stromal cells. However, in adenoma samples, the crypt 
structure is completely lost accompanied with  a significant and distorted 
expression of PRLR (Fig 3.4 C, D). Further more in some cells, nucelar staining 
for PRLR was also observed. Histoscore analysis indicated a significant increase in 
PRLR expression in adenomas and adenocarcinomas (Fig 3.5 A). In addition, this 
increase occurs in a stage specific manner with decresed expression noted in 
inflammation and polyps while increased expression was observed in adenomas 
and adenocarcinomas (Fig 3.5 B). 
3.4.4 Analysis of PRLR expression in metastatic sites 
Further histological analysis of samples derived from distant metastatic sites such 
as lymph nodes and liver indicates that the increase in PRLR expression observed 
in adenomas and adenocarcinomas is maintained in these metastatic foci localized 
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to these regions. Lymph nodes have a lower level and diffuse expression of PRLR 
(Fig 3.6 A, B), however, metastatic foci have significantly higher levels of PRLR 
compared to surrounding tissue (Fig 3.6 C, D). Normal liver samples (Fig 3.7 A, 
B) have a significant higher PRLR expression compared to metastatic foci (Fig 3.7 
C, D). Histoscore analysis also indicates the same with higher PRLR expression in 
metastatic foci of the lymph nodes as compared to liver site (Fig 3.8 A).  
3.4.5 TCGA based evaluation of changes in PRLR expression 
Changes in the expression of a particular gene can occur due to a number of 
reasons, including chromosomal anomalies. Numerical variations, referred to as 
copy number variations (CNV), constitute one of the frequently observed 
chromosomal variations in most cancers [251]. The Cancer Genome Atlas 
(TCGA), data sets containing expression and CNV data pertaining to PRLR and 
four other genes flanking the PRLR gene DNAJC21, RAL14, RAD1 and Alanine-
glyoxylate aminotransferase 2 (AGXT2), were analyzed to determine whether the 
increase in expression was due to underlying genetic variation. We noted a 
significant increase in expression of PRLR, DNAJC21, RAD1 and RAL14 in 35- 
40% of patient samples (Fig 3.9 A, B, C and D). AGXT2, on the other hand, did not 
show any significant change in expression (Fig 3.9 E). The remaining patient 
population had a decrease in expression of PRLR; however, the decrease is not 
statistically significant.  
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Figure 3.4: Histological analysis of PRLR expression in CRC and adjacent 
normal tissue 
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Figure 3.4: Histological analysis of PRLR expression in CRC and adjacent 
normal tissue: (A, B) PRLR is expressed at very low levels and is primarily  
localized to the basolateral membrane surface. (C- F) In colorectal tumor samples, 
the crypt structure is completely distorted accompanied with an overall increase in 
PRLR expression in all the cells of the tumor. A few cells also show nuclear 
staining. 
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Figure 3.5: Histoscore analysis of PRLR expression in normal and CRC tissue 
samples 
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Figure 3.5: Histoscore analysis of PRLR expression in normal and CRC tissue 
samples: (A) In comparison to normal colon sections, increased expression of 
PRLR is observed in adenomas and adenocarcinomas. (B) However, during the 
initial stages of CRC progression, that is during inflammation and polyps, a 
decraese in PRLR expression is observed.  
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Figure 3.6: Histological analysis of PRLR expression in lymph node metastatis 
site 
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Figure 3.6: Histological analysis of PRLR expression in lymph node metastatis 
site: (A, B) Normal lymph exhibits diffused PRLR staining. C,D) metastatic foci 
in the lymph node expressed higher levels of PRLR compared to surrounding 
lymph nodes tissue. Metastasis also led to complete loss of tissue integrity. 
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Figure 3.7: Histological analysis of PRLR expression in liver metastatis site 
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Figure 3.7: Histological analysis of PRLR expression in liver metastatis site: 
(A) PRLR is expressed at high levels in a diffuse manner with deep staining in the 
nuclei of some cells. (B) Metastatic foci have higher PRLR expression. 
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Figure 3.8: Histoscore analysis of PRLR expression in metastatic sites 
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Figure 3.8: Histoscore analysis of PRLR expression in metastatic sites: (A) 
Compared to normal intestinal tissue, PRLR expression is increased in adenomas 
and adenocarcinomas and increases further in lymph node metastatic sites. 
However, in the liver metastatic foci PRLR expression is decreased. 
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Figure 3.9:  Evaluating changes in expression of genes located in the PRLR 
locus 
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Figure 3.9:  Evaluating changes in expression of genes located in the PRLR 
locus: Expression data sets pertaining to genes DNAJC21, RAD1, RAL14, AGXT2 
which are in close vicinity of PRLR gene for 156 patients was obtained from 
TCGA data base. Data indicates that there is a significant increase in expression of 
(A) PRLR, (B) DNAJC21, (C) RAD1and (D) RAl14 in 30-40% of patient 
population, while expression of  (E) AGXT2 seems to increase, but is not stastically 
significant. *= p<0.05. 
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Figure 3.10:  Evaluating changes in the copy number of genes located in the 
PRLR locus 
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Figure 3.10:  Evaluating changes in the copy number of genes located in the 
PRLR locus: Patient data sets pertaining to copy number analysis for DNAJC21, 
RAD1, RAL14, AGXT2 genes which are in close vicinity of PRLR gene for 156 
patients was obtained from TCGA data base. Data indicates that there was a 
significant increase in copy number of (A) PRLR, (C) RAD1, (D) RAl14 and (E) 
AGXT2 while the copy numer of (B) DNAJC21 does not change significantly (*= p 
≤ 0.05). 
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In addition to the expression data, we also evaluated for any changes in the copy 
number as an increase in copy number has also been identified as a contributory 
factor for increase in gene expression [252]. TCGA analysis demonstrated that 
there is a significant increase in mean copy number of PRLR, RAD21, RAL14 and 
AGXT2 (Fig 3.10, A, C, D, E) with no significant change in DNAJC21 (Fig 3.10 
B). Next we performed a correlation and regression analysis on normalized data to 
identify existence of correlation between the increase in expression and the CNV 
of the genes. Data indicates a strong correlation in the increase in expression of 
PRLR, DNAJC21, RAD1 and RAL14 (Fig 3.11 A, B, C, D) with an increase in copy 
number of these genes indicated by a positive correlation, while in the case of 
AGXT2, this correlation is lost (Fig 3.11 E). 
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Figure 3.11:  Evaluating changes in the copy number of genes located in the 
PRLR locus 
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Figure 3.11:  Evaluating changes in the copy number of genes located in the 
PRLR locus: Correlation analysis to identify if there is a relationship between the 
observed changes in expression and copy number. It may be speculated that the 
increase in expression observed in (A) PRLR, (B) DNAJC21,  (C) RAD1and (D) 
RAl14 may be due to an increase in copy number of the genes in some patients. 
Such positive correlation did not exist in the case of (E) AGXT2.  
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3.4.6 Intrinsic transcription factors which regulate PRLR expression 
In the above study, some patients show an increase in PRLR gene expression but 
no change in copy number, suggesting a different mechanism. To identify the 
cause for increase in expression of PRLR noted in these samples, we investigated 
the intrinsic transcription enhancer factors that can potentially regulate PRLR 
expression. We analyzed the 2.5 Kb promoter upstream region for PRLR 
transcription start site for several transcription enhancers (Table 2.1). Of the 
multiple factors, we identified only three, SREBP1, NR2F1 and GFI1, that had 
single binding sites. Real-time PCR analysis to identify expression levels of these 
factors in colorectal cancer cells shows that HCT116 cells have a  significant 
increase in expression of SREBP-1 compared to other cells types (Fig 3.12 A) and 
is predominantly localized to the nucleus (Fig 3.12 B). Based on this, we directed 
our further studies to identify if SREBP-1, which can regulate expression of 
metabolic genes [247], is also involved in regulating PRLR expression in CRC. To 
this end, chromatin-immuno precipitation followed by semi-quantative real-time 
PCR was performed using two different primer pairs which flank the SREBP-1 
binding sites of PRLR enhancer region (Fig 3.12 C). There was an increase in 
SREBP-1 occupancy in HCT116 cells, compared to isotype control (Fig 3.12 D). 
Collectively, this data suggests that expression of PRLR in CRC patients can be 
regulated individually or in combination by in CNV or an increase in transcription.  
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Figure 3.12:  Evaluating SREBP-1 expression and its occupancy of the PRLR 
enhancer elements. 
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Figure 3.12:  Evaluating SREBP-1 expression and its occupancy of the PRLR 
enhancer elements: (A) Evaluating expression of three transcription enhancer 
proteins which have a single binding site in the PRLR promoter region. Data 
indicates that SREBP-1 was upregulated in HCT116, DLD1 and SW620. (B) 
Western blot indicates that SREBP-1 accumulated in the nucleus.  (C) Depiction of 
SREBP-1 binding site in the PRLR enhancer region, two primers of 114 and 415 
bp were designed to evaluate binding. (D) ChIP data indicating active recruitment 
of SREBP-1 onto the PRLR promoter region.  
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3.5 Discussion 
PRLR is a single pass non-tyrosine kinase receptor belonging to the class 1 
cytokine receptor family. Localized to chromosome 5p13-14, it contains 10 exons 
and codes for a single transcript, which is then alternately spliced to generate 
diverse functional isoforms. Binding of PRL leads to dimerization of the receptor 
and activation of intracellular signaling mediated predominantly by JAK-STAT or 
JAK-ERK pathways. Several tissues have been identified to express PRLR where 
it plays a critical role in tumorigenesis. Our earlier studies have shown that CRC 
cells treated with recombinant PRL show  activation of Jak2- STAT3 signaling, 
clearly demonstrating the presence of functional PRLR in CRC cells [253]. In 
humans, PRL is only known to interact with PRLR. This intrigued us to evaluate 
the levels and pattern of PRLR expression in patient population and to identify if 
there is existence of any heterogeneity in the expression pattern with an intention 
to exploit it as a diagnostic tool.  
For the ease of desigining primers, we catagorized, PRLR isoforms into two major 
groups. The full length and the dSF1 forms were grouped into long form and the 
SF1a, SF1b and d7/11 isoforms were grouped as short form (Chapter 1, Fig 1.7). 
We evaluated the expression of PRLR in various regions of the GI tract and 
identified that the long form is predominantly expressed in the intestinal region. 
The long form was expressed more in the colon compared to short form, which is 
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expressed at varying level across the GI tract (Fig 3.2 A, B). Next we evaluated 
PRLR expression in CRC patient samples, and observed an increase in the 
expression of both the long and the short form of PRLR transcripts in a cohort of 
patient samples. However, the levels of long form of receptor is higher than that of 
the short form (Fig 3.3 A, B). Similar findings were reported earlier [99, 223]; 
however, our study provides in depth analysis and demonstrates an isoform 
dependent variation in expression of PRLR. The increase in long form of PRLR 
compared to short forms clearly indicates that PRL signaling potentially plays a 
significant role in CRC tumorigenesis.  
Next, we evaluated PRLR expression in tissue sections pertaining to tumor and 
adjacent normal samples. PRLR is expressed both in normal (Fig 3.4 A,B) and 
malignant sections (Fig 3.4 C,D). It is expressed in all the cells lining the crypt and 
predominantly on the basolateral membrane surface. However, in malignant 
samples the crypt structure is completely lost with a distorted expression pattern of 
PRLR, a finding further supported by histoscore analysis (Fig 3.5 A). PRLR 
expression is decreased in the initial stages of CRC (such as the inflammatory 
stages) as compared to adenoma and adenocarcinoma (Fig 3.5 B). These data 
clearly indicate that PRLR expression changes in a stage specific manner with 
higher expression observed in malignant tissue. This increase in PRLR expression 
is retained in metastatic sites of lymph nodes (Fig 2.6 B) and liver (Fig 3.7 B), 
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where invasion leads to loss of native tissue structure and formation of metastatic 
foci.  
We next analyzed gene expression and CNV data sets derived from TCGA datasets 
to identify the underlying reason for the observed increase in PRLR levels in  
colorectal cancer patient samples. Our data suggest that there is increase in 
expression of PRLR, including  DNAJC21, RAD1, RAL14 and AGXT2 genes 
located in the same locus. These genes have also been shown to play a critical role 
in tumorigenesis of various cancer types. In addition, PRLR, RAL14, RAD1 and 
DNAJC21 genes also exhibited an increase in gene copy number (Fig 3.8- 3.10). 
There exists a correlation between the increase in expression and increase in copy 
number of PRLR, RAL14 and RAD1 genes. However, DNAJC21 did not follow that 
relationship, there was a increase in expression but no change in CNV. AGXT2 on 
the other hand shows only an increase in copy number but not expression. This 
may have been due to improper design of probe sets used to quantify changes in 
expression and CNV or changes in promoter region of this gene.  
We next evaluated whether, there are any intrinsic factors that can regulate 
expression of PRLR. For this, we analyzed the 2.0 kb region upstream of the 
transcriptional start site for PRLR gene. Consences sequences for binding of 
several transcription enhancer factors was found in this region (Table 3.1). 
However, among the factors which have unique binding sites, only SREPB-1 
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seemd to be expressed at high levels compared to other factors. SREBP-1 plays a 
critical role in lipid biosynthesis and energy homeostasis in CRC. Our findings, 
based on ChIP analysis followed by real-time PCR, clearly indicate that SREBP-1 
can potentially bind to and regulate the expression of PRLR.   
Collectively, our findings indicate increase in expression of PRLR in colorectal 
tumor samples compared to normal samples. We also demonstrate that PRLR is 
expressed in normal colon crypt and is predominantly localized to the membrane. 
The study also suggests that the increase in expression may be a combined 
contribution of increase in copy number of PRLR gene and an increase in 
transcription, facilitated by increased binding of enhancer factor to the promoter 
proximal region of the PRLR gene. Further studies directed towards cytological 
evaluation to validate this increase in copy number and including a wider 
population may provide a clearer view of the expression pattern of PRLR in CRC 
and may provide new directions in evaluating PRLR based early diagnostic tools 
for detection of CRC.  
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Table 3.1: List of transcription factors or enhancers that have potential 
binding sites in the 2 Kb region upstream of the PRLR promoter 
region. 
 
Transcription 
factor/ enhancer 
Number of 
sites 
CDX2 70 
AML1a 16 
SRY 51 
GATA-X 3 
MZF1 8 
CP2 4 
GATA2 12 
GATA1 28 
LYF1 3 
DeltaE 6 
NKX2 5 
SREBP1 1 
USF 8 
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TST1 4 
S8 5 
OCT1 11 
EVI7 6 
AP1 9 
P300 1 
C/EBPB 5 
c-ETS 9 
SP1 1 
IK2 5 
AP4 1 
C-REL 4 
COUPT 1 
HNF3b 11 
XFD1 1 
N-MYC 2 
CDPCR 2 
GFI1 1 
HFH2 10 
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Chapter 4 
Discussion and future direction 
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4.1 Discussion 
PRL was identified in the early 1920’s [75, 76] and since then it has been shown to 
affect a diverse array of physiological activities. Released in a circadian manner 
[254] from the pituitary, PRL regulates stress related responses [110]. In humans 
PRL regulates reproduction [255] and milk production and secretion [118] and 
cancer [123]. Even though at a slow rate, new attributes are continuously being 
connected or advocated as being caused by PRL, such as its role in regulating the 
normal neuronal stem cell population [155], including our finding that it regulates 
cancer stem cells [253] in colorectal cancers.  
The first evidence of the role of PRL in GI tract comes from the work of Muller 
and Dowling [141] who induced hyperprolactinemia by injecting perphenazine, an 
antipsychotic drug that increased PRL secretion (as a side effect) [256] and found 
that this led to an increase in mucosal hyperplasia. Nagano and colleagues later 
identified that PRLR is expressed in the intestine [177], additional studies have 
shown that intestinal PRL can regulate calcium homeostasis and ion transport [142, 
209]. Clinically high serum levels of PRL was observed in patients with colorectal 
cancer [147]. Surgical removal of the tumor led to normalization of serum PRL 
levels, based on these observations; the authors propose the use of serum PRL as a 
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better prognostic marker for early detection of CRC. On similar lines, an increase 
in PRLR expression was observed in CRC tumors [223]. These findings implicate 
that expression of both PRL and PRLR is upregulated in CRC patients. However, 
the biological significance of this upregulation and the intracellular signaling 
pathways which are activated or regulated by PRL via PRLR in CRC remain 
elusive. Similarly, the expression pattern of PRLR in normal GI tract and how the 
expression varies in CRC has not been well characterized. This thesis is aimed at 
providing a clear understanding of the signaling induced by PRL and to identifying 
the expression pattern of PRLR in normal GI tract and in CRC, in order to develop 
better diagnostic/ prognostic tools and identify therapeutic agents to inhibit PRL-
PRLR signaling.  
4.2 Intracellular pathways activated by PRL in CRC 
The first part of this dissertation deals with understanding the intracellular 
signaling pathways that are activated by PRL in CRC. Based on in vitro studies, 
using established colorectal cancer cell lines, we first showed that PRLR is 
expressed at varied levels in these cells implicating that they are PRL responsive. 
Second, culturing these CRC cells in presence of recombinant PRL showed an 
increase in spheroid formation, an assay used to quantify the presence of stem 
cells. In addition, we showed that PRL induces, JAK2, STAT3 and ERK 
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phosphorylation. JAK, STAT and ERK family of proteins are established “signal 
transducers” which are responsible for transducing an extracellular event to the 
nucleus either directly or through other accessory proteins to induce changes in 
gene expression in response to extracellular cues [257].  
PRL activates JAK2- STAT5 signaling pathways in breast cancer [258] and 
prostate cancer [153]. However in CRC, we showed that PRL activates JAK2- 
STAT3-ERK pathway compared to other cancer types. Several publications 
including our own (Chapter 2, Fig 2.4) have demonstrated that the basal level of 
STAT5 in the CRC cells lines used in this study significantly low. This implicates 
that PRL can differentially activate either STAT5 or STAT3 depending on the cell 
type and abundance of STAT proteins. The differential activation also implicates 
different downstream effect, such as STAT5 promotes proliferation, but STAT3 
does not [259].  This may be the reason that we did not observe a change in 
proliferation in our study (Fig 4.1). However, we observe an increase in cancer 
stem cell population (Chapter 2, Fig 2.5).   
Notch signaling, as elaborated in Chapter 1, is critical in regulating colorectal 
cancer stem cell population. The fact that PRL can regulate CRC stem cell 
population, by inducing Notch signaling, suggests that it can activate additional 
pathways that help coordinate its action on stem cells. Goh and colleagues 
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demonstrated that phosphorylated ERK can induce JAG1, a Notch receptor ligand 
[216]. We have demonstrated that PRL treatment induces JAG1 expression which 
in turn activates Notch signaling pathway. These results indicate that PRL can 
activate not only JAK-STAT-ERK pathways, but also accessory pathways that can 
regulate critical events in colorectal tumorigenesis. 
4.3 Expression pattern of PRLR in colorectal cancer 
Next, we looked at levels of PRLR, which is critical in regulating PRL induced 
signaling in CRC. In a patient population based study, we observed an increase in 
PRLR expression in CRC tissue compared to adjacent normal tissue samples. 
Similarly, histological analysis shows an increased PRLR staining in CRC biopsy 
samples compared to adjacent normal tissue (Chapter 3, Fig 3.3- 3.5). Similar 
changes in expression pattern of PRLR was earlier reported in breast cancer [175] 
where tumor specific increases in PRLR expression were observed. However a 
similar and dramatic change in PRLR expression is also seen in normal breast 
tissue under varied physiological condition limiting its application as a prognostic 
tool in breast tumors. In comparison, an increase in PRLR distinctly in CRC tissue 
compared to adjacent normal, may implicate its diagnostic relevance. 
Some of the histological sections and in vitro studies show nuclear localization of 
PRLR particularly in CRC cells treated with PRL (Fig 4.2). Similar nuclear  
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Fig 4.1: Presence of PRL does not induce proliferation neither does it induce 
cell death.  
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Fig 4.1: Presence of PRL does not induce proliferation neither does it induce 
cell death proteins: (A) HCT116, HT29, SW480 and SW620 colorectal cancer 
cells treated with exogenous PRL for 24 and 48 hours do not show any increase in 
proliferation. (B) An increase in Cyclin E levels, clearly implicate active PRL 
signaling, however an absence in increase in Cyclin D, a critical protein to promote 
S-G1 transition, suggest that PRL treatment may not induce proliferation. 
Similarly, an absence of PARP cleavage and an increase in levels of anti-apoptic 
protein BCL2, suggest that prolactin may prevent cell death in CRC cell lines. 
 
 
 
 
4.2: Nuclear localization of PRLR upon PRL treatment in CRC 
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4.2: Nuclear localization of PRLR upon PRL treatment in CRC: CRC cells 
treated with exogenous PRL (500 ng/ml) led to nuclear translocation of PRLR as 
early as a 1h post treatment as compared to untreated sample. At 3h, there was a 
decrease in nuclear and membrane localization of PRLR but the cytoplasmic levels 
remain unchanged. 
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localization of PRLR was observed in breast cancer tissue [260] where it can bind 
to HMGN2 to induce expression of STAT5 responsive genes. Given the fact that, 
PRL signaling in CRC leads specifically to STAT3 activation and that STAT3 and 
STAT5 activate different sets of genes, it will be interesting to identify the proteins 
that can interact with PRLR in CRC and the genes that are regulated by this 
complex.  
4.4 Future Directions 
4.4.1 Analyzing PRLR locus amplification 
In silico data analyzed and presented earlier (Chapter 3, Fig 3.9- 3.11) clearly 
indicate the possibility of occurrence of locus amplification. Several early reports 
indicate similar amplification in genes in other cancers that have been exploited as 
diagnostic tools [261, 262]. These chromosomal amplifications can be identified 
using PCR [263] or through chromosomal staining. Current focus in the lab is 
directed towards identifying means to analyze 5p13-14 locus amplification in 
colorectal cancer. Data from this analysis would help us develop novel diagnostic 
tool for early detection of CRC. 
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4.4.2 Identifying novel small molecular inhibitors to target JAK-STAT 
signaling 
Data presented in Chapter 2 indicates that PRL actives JAK-STAT pathway in 
CRC cell lines. In addition, the dose and time dependent increase in STAT3- 
luciferase activity further supports the observation. The lab intends to use this 
plasmid to scan for novel STAT3 inhibitors, from the existing small molecule 
library available at the NCI and KU repository.  
4.4.3 Evaluating SREBP-1 binding to the PRLR enhancer elements  
Data presented in Chapter 3, clearly demonstrates that SREBP-1 can bind to the 
enhancer region of the PRLR gene. SREBP-1 binds to a specific sequence known 
as Sterol Response Element- 1 (SRE-1) in the enhancer region. Current studies in 
the lab are focused on cloning wild type and mutated SRE element upstream of a 
luciferase promoter. The luciferase activity from this plasmid would be used as a 
read out for the active binding of SREBP-1 to the PRLR promoter regions. 
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